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Estrogens are female sex hormones, belonging to a group of steroids, and they are 
responsible for the sexual characteristics of the female (Gruber et al., 2002). They 
also have effects on bone, cardiovascular system, brain, and skin. The main human 
estrogens are estrone (E1) 1, estradiol (E2) 2, and estriol (E3) 3 (Fig. 1). Biologically 
the most active and abundant estrogen is estradiol 2. The estrogen actions occur 
through the binding of the estrogens to estrogen receptors. The estrogen receptors α 
and β — the latter found by Gustafsson’s group (Kuiper et al., 1996) in 1996 — are 
present in various tissues. Estrogen fatty acid esters are a lipophilic form of 
estrogens, thought to function as estrogen storage in adipose tissue. Estrogens are 
also produced in the male and they play an important role in spermatogenesis, 
cardiovascular health and bone homeostasis (de Ronde et al., 2003). Estrogens are 
found in the endocrine systems of all vertebrates (Lange et al., 2002). The horse 
produces special estrogens, namely equilin 4 and equilenin 5 (Fig. 1). Estrogens also 
occur in the plant kingdom, in small quantities for example in pomegranate (Punica 
granatum), date palm (Phoenix dactylifera), beans (Phaseolus vulgaris), and olive 
tree (Olea europea).  
 
Figure 1. Structures of the main human estrogens estrone 1, estradiol 2, and estriol 3, together with 
horse estrogens equilin 4 and equilenin 5. 
 
Estrone 1 was first isolated from pregnancy urine and crystallized in 1929 
concurrently by two groups, Doisy in the United States and Butenandt in Germany 
(Butenandt, 1979). Estriol 3 was isolated in 1930 and estradiol 2 in 1936. Estrone 1 
(Latin oestrus meaning frenzy) was originally named theelin (Greek thelon for 
female), and estriol 3 was called tell (Adam and Rosenheim, 1993), Anner and 
Miescher (Anner, 1948) announced the first total synthesis of estrone 1 in 1948. 
Although estrogens have been studied for almost a century, the research continues. 
Estrogen metabolites and derivatives have been subjects of great interest. The 
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metabolite 2-methoxyestradiol 6 is an especially promising antitumor agent as well 
as a potential drug candidate (Lakhani et al., 2003). 
Oral and transdermal estrogens are used in hormone replacement therapy (HRT), 
usually together with progesterone, to relieve menopausal symptoms in women. The 
benefits and risks of HRT have been extensively evaluated. HRT has beneficial 
effects on osteoporosis and it is protective against cardiovascular disease, but it 
increases the risk of breast cancer and may cause thromboembolic disease . Whereas 
synthetic estrogens are used in HRT in Europe, conjugated equine estrogens 
extracted from urine of the pregnant horse are common in the United States. These 
equine products comprise several different estrogens, which are further converted to 
various metabolites (Turgeon et al., 2004). 
 
ESTROGEN BIOSYNTHESIS 
Estrogens are the end products of a long biosynthetic pathway starting from squalene 
and proceeding through cholesterol 12 to androgens (Ackerman and Carr, 2002). The 
biosynthetic pathway has been studied by adding, in vivo or in vitro, 14C-labeled 
cholesterol, progesterone or androgens and detecting the formed radiolabeled 
estrogen (Morand and Lyall, 1968). Testosterone 8 is oxidized twice at C-19 by 
steroid 19-hydroxylase and then aromatized by aromatase (CYP 19) to estradiol 
(Ackerman and Carr, 2002) 17β-Hydroxysteroid dehydrogenase (17β-HSD) is 
responsible for the interconversion of estradiol and estrone. The reductive isoform 
17β-HSD type 1 converts E1 1 to E2 2, and the oxidative isoform 17β-HSD type 2 
acts in the opposite way. In women, estrogen biosynthesis occurs mainly in the 
ovaries in premenopausal women and in adipose tissue in the post menopausal 
women, but also local biosynthesis occurs in a number of sites including in breast, 
brain, and bone (Gruber et al., 2002). 
 
ESTROGEN METABOLISM 
The oxidative metabolism of estrogens is performed by cytochrome P450 enzyme 
families mainly in the liver. Oxidation by P450 isoforms can occur at almost every 
position in the estrogen skeleton and over 40 metabolites have been identified in 
biological samples from humans or animals or in vitro incubations (Zhu and Conney, 
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1998). In humans, estrogen metabolism consists mainly of the 15 metabolites. 
Several pathways can be distinguished in estrogen metabolism, the main ones being 
the 2-hydroxylation and 16α-hydroxylation pathways. A minor pathway is the 4-
hydroxylation pathway. The O-methylation of catechol estrogens is catalyzed by 
catechol-Omethyltransferase (COMT). Eventually the metabolites are converted to 
inactive, water-soluble glucuronides and sulfates and excreted in the urine or feces. 
 
ESTROGEN RECEPTORS 
 
 
Figure 1. Schematic representation of oestrogen receptor localisation in female human tissues. 
 
Cellular signaling of estrogens is mediated through two ERs, ERα (NR3A1) and ERβ 
(NR3A2), both belonging to the nuclear receptor (NR) family of transcription 
factors. Like many other members of the NR family, ERs contain evolutionarily 
conserved structurally and functionally distinct domains. The central and most 
conserved domain, the DNA-binding domain (DBD), is involved in DNA 
recognition and binding, whereas ligand binding occurs in the COOH-terminal 
multifunctional ligand-binding domain (LBD). The NH2-terminal domain is not 
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conserved and represents the most variable domain both in sequence and length. 
Transcriptional activation is facilitated by two distinct activation functions (AF), the  
constitutively active AF-1 located at the NH2 terminus of the receptor and the 
ligand-dependent AF-2 that resides in the COOH-terminal LBD. Both AF domains 
recruit a range of coregulatory protein complexes to the DNA-bound receptor. The 
two ERs share a high degree of sequence homology except in their NH2- terminal 
domains, and they have similar affinities for E2 and bind the same DNA response 
elements. Ligand-dependent estrogen signaling begins with the binding of estrogen 
to ER. Thereafter, the cell-specific transcriptional response to estrogen depends on 
multiple factors, the most immediate being the composition of coregulatory proteins 
in a given cell and the characteristics of the promoters of estrogen responsive genes. 
Since hormones are modulators of transcription, the pattern of modulated genes also 
depends on what other signaling pathways are active in the cell at the time of 
hormone exposure (Katzenellenbogen et al., 1996; Nilsson et al., 2001; 
Katzenellenbogen and Katzenellenbogen, 2002). 
The identification of the second estrogen receptor ERβ and several receptor isoforms 
has affirmed the complex nature of estrogen signaling and helped to explain estrogen 
action in tissues that do not express ERα. ERα and ERβ are products of separate 
genes located on different chromosomes (Menasce et al., 1993; Enmark et al., 1997). 
Several splice variants have been described for both receptor subtypes, but whether 
all the variants are expressed as functional proteins with biological functions is not 
clear. Most ERα variants differ in their 5’-untranslated region (UTR), not in the 
coding sequence. In addition, shorter ERα isoforms lacking exon 1 and consequently 
the NH2-terminal AF-1 (here termed hERα-46 and hERα-36) have been isolated and 
identified in different cell lines (Flouriot et al., 2000; Wang et al., 2005). These 
receptor isoforms have not yet been identified or characterized in tissues, and their 
involvement in regulating estrogen effects in vivo remains to be determined. They 
are, however, interesting research tools since they have the ability to heterodimerize 
with the full-length ERα and thereby repress AF-1-mediated activity (Flouriot et al., 
2000; Wang et al., 2005). Possibly, they may also localize to the plasma membrane 
and may help to elucidate the mechanisms through which rapid, “nongenomic” 
estrogen signaling occurs (Li et al., 2003; Wang et al., 2005). 
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Figure 2. Schematic representation of estrogen receptor alpha isoforms. The domains of the 
receptors include DBD, LBD, and two transcriptional activation functions, AF-1 and AF-2 as 
indicated for hERα. Full-length human ERα is 595 amino acids long. Both short ERα isoforms, hERα-
46 and hERα-36, lack the NH2-terminal region harboring AF-1. 
 
Unlike ERα, several splice variants of ERβ are expressed in tissues. The 530-amino 
acid (aa)-long human ERβ isoform is currently regarded as the wild-type ERβ (rat 
and mouse, 549 aa) (Leygue et al., 1998). 
Several alternative ERβ isoforms have been described, and many of these are 
expressed as proteins in tissues (Fuqua et al., 1999; Saji et al., 2002). 
Characterization of the functional isoform pattern in human samples is not complete, 
but several experiments indicate that ERβ isoforms can differentially modulate 
estrogen signalling and, as a consequence, impact target gene regulation (Matthews 
and Gustafsson, 2003; Ramsey et al., 2004; Leung et al., 2006). For example, the 
human ERβ2 isoform (also named ERβ cx) with 26 unique aa residues replacing the 
COOH-terminal part of the LBD is unable to bind ligand or coactivators and has no 
transcriptional activity in reporter assays. ERβ2 dimerizes with preferentially ERα, 
thereby silencing signaling via this ER isoform (Ogawa et al., 1998). Both species-
specific and species-common ERβ isoforms have been identified (Lewandowski et 
al., 2002). 
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Figure 3. Schematic representation of estrogen receptor beta isoforms. The 530-amino acid-long 
hERβ isoform is currently regarded as the full-length wild-type hERβ. Note that deletion of the fifth 
exon giving the hERβ exon 5 isoform results in a frameshift and a termination of the protein before 
the LBD. The striped fill patterns of the 3’ end of hERβ2 (also named hERβcx), hERβ4, and hERβ5 
represent the differing COOH terminal regions of these isoforms. The full-length rat and mouse ERβ 
isoforms are 549 amino acids and have 99% sequence similarity. The mERβ2 and rERβ2 isoforms 
contain an 18-amino acid insertion in the LBD, causing a significant decrease in ligand binding 
affinity. Deletion of exon 3 results in rat isoforms unable to bind DNA, and the observed deletion of 
exon 5 and/or 6 in mice results in isoforms lacking various parts of the LBD. 
 
In the late 1990s, a putative GPCR was cloned by four different groups using highly 
disparate approaches ( Owman et al., 1996; Carmeci et al., 1997; Takada et al., 1997; 
O'Dowd et al., 1998). The GPCR identified in these studies displayed little homology 
to other GPCRs. GPR30 mRNA was shown to be expressed in numerous tissues 
throughout the body (e.g. placenta, lung liver, prostate, ovary, placenta) although 
substantial contradictions between the tissue expression patterns were reported. Since 
no ligand was known for this receptor, it was labeled an orphan GPCR. It was not 
until 2000 that a possible function for this GPCR was identified from experiments 
demonstrating MAP kinase (Erk1/2) activation by estrogen, as well as ER 
antagonists, ICI 182,780 and tamoxifen. GPR30 is a G protein-coupled seven-
transmembrane receptor, and human GPR30 comprises 375 amino acids with a 
theoretical molecular mass of approximately 41 kDa. It is thought that the N-
terminus is located outside of the cell, and that aspartic acid residues in the terminal 
region might be modified by glycosylation if GPR30 is localized in the plasma 
membrane. It is speculated that the ligand associates with the N-terminal domain to 
activate the receptor. Trimeric G protein is presumed to bind to the 3rd loop of the 
intracellular domain based on the molecular structure. A PDZ domain appears to be 
in the C-terminal region of GPR30, but its physiological role is unknown. 
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Figure 6. Two-dimensional schematic of a generic GPCR set in a Lipid Raft. 
 
Given that GPR30 and the classical ERs share a common ligand, the question arose 
as to the relative selectivity of each receptor type for estrogenic substances. Estrogen 
is a small ligand with no conformational flexibility and limited sites of stereospecific 
recognition. Thus, it might be predicted that two receptors (with no homology in 
primary or secondary structure) that both bind estrogen, would bind a similar 
spectrum of structurally related compounds. As described below, a large number of 
compounds that bind to classical estrogen receptors have also been demonstrated to 
bind to or activate GPR30. 
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Molecular pathways of Estrogen Receptors 
There are several distinct pathways by which estrogens and ERs may regulate 
biological processes (Hall et al., 2001). 
 
 
Figure 5. Model representing the mechanistically distinct molecular pathways used in the regulatory 
actions of ERs.  
 
Ligand-bound ERs can bind directly to estrogen response elements (ERE), in the 
promoters of target genes or can interact with other transcription factor complexes 
like Fos/Jun (AP-1- responsive elements) (Kushner et al., 2000) or SP-1 (GC-rich 
SP-1 motifs) (Saville et al., 2000) and influence transcription of genes whose 
promoters do not harbor EREs. Ligand-dependent activation triggers recruitment of a 
variety of coregulators to the receptor in a complex that alters chromatin structure 
and facilitates recruitment of the RNA polymerase II (Pol II) transcriptional 
machinery. The details of ER-transcription factor interactions (i.e., ligand specificity, 
ER subtype specificity, interaction domains and motifs) remains to be characterized. 
Interestingly, in certain cell-type and promoter contexts, 4-hydroxytamoxifen and 
raloxifene, which function as antagonists at EREs, can behave as agonists through 
these indirect pathways. ERβ, but not ERα, in the presence of E2 can oppose the 
actions of 4-hydroxytamoxifen and raloxifene on an AP-1 reporter gene (Paech et al., 
1997; Webb et al., 1999). Similar observations have been made for the SP-1 pathway 
( Zou et al., 1999; Saville et al., 2000). 
In addition to the well-studied transcriptional effects of E2, there are rapid effects, 
i.e., occurring within seconds or minutes after addition of E2 (Wong et al., 2002 Song 
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et al., 2005; Song and Santen, 2006; Warner and Gustafsson, 2006). These rapid 
effects include activation of kinases and phosphatases and increases in ion fluxes 
across membranes. Although these rapid effects have been extensively studied, there 
is still no consensus as to whether or not the classical ERs are involved (Deecher et 
al., 2003; Razandi et al., 2004) or whether there is a distinct membrane associated 
receptor (Doolan and Harvey, 2003). Tools such as pathway-selective ligands 
(Harrington et al., 2006) or cell lines designed to selectively express ERβ in the 
nucleus, cytoplasm, or membrane may prove useful in studying these extranuclear 
ER actions (Santen et al., 2005). Interestingly, evolutionary evidence suggests that 
early on, estrogen influenced reproduction through ER-independent pathways (Keay 
et al., 2006) and that the receptor was unresponsive to estrogens and acted as a 
constitutive transcriptional activator (Keay et al., 2006; Thornton et al., 2003). When 
the two ER subtypes are coexpressed in cells, ERβ can antagonize ERα-dependent 
transcription (Matsumoto and Arai, 1979; Matthews et al., 2006). The molecular 
mechanisms of ERβ-mediated inhibition of ERα signaling are currently under 
investigation. For example, it was shown that for ERα-mediated regulation of AP-1-
dependent transcription, ERβ expression alters the recruitment patterns of c-Fos to 
AP-1-regulated promoters. Moreover, expression of ERβ and the ERβ variant ERβ2 
increases the proteolytic degradation of ERα (Matthews et al., 2006). Collectively, 
these data suggest that the ERβ-mediated inhibition of ERα activity involves a 
combination of altered recruitment of key transcription factors and increased ERα 
degradation. In addition to ligand-induced transcriptional activities of ER, ligand-
independent pathways to activate ERs have been described. Growth factor signaling 
leads to activation of kinases that may phosphorylate and thereby activate ERs or 
associated coregulators in the absence of ligand (Kato et al., 1995). The growth 
factor activated pathway is thought to significantly contribute to hormone-
independent growth in some tumors (Coutts and Murphy, 1998; Shim et al., 2000). 
From these examples, it is clear that estrogen can mediate a multitude of complex 
rapid cellular activation events. However, not all such responses can be attributed to 
the classical ERs. Upon agonist binding, GPR30 activates heterotrimeric G proteins, 
which in turn can activate multiple effectors, including adenylyl cyclase (resulting in 
cAMP production), Src, and sphingosine kinase (SphK). The latter two pathways 
appear to be involved in the activation of matrix metalloproteinases (MMPs), which 
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cleave pro-HB-EGF, releasing free HB-EGF that can then transactivate epidermal 
growth factor receptors (EGFRs). EGFR activation leads to multiple downstream 
events, including the activation of phospholipase C (PLC), mitogen-activated protein 
kinases (MAPKs), and phosphatidylinositol 3-kinases (PI3Ks). PLC activation leads 
to intracellular calcium mobilization through the actions of inositol triphosphate 
(IP3). The activation of MAPKs and PI3Ks results in the activation of numerous 
cytosolic pathways as well as the activation of nuclear proteins that are themselves or 
that regulate transcription factors. Thus, estrogen stimulation can give rise to the 
transcription of gene targets whose promoters do not contain steroid response 
elements. The combined effects of these cytosolic signalling and nuclear 
transcription events often result in cell proliferation. 
 
 
Figure 6. Mechanisms of estrogen-mediated signaling through GPR30. 
 
 
FUNCTIONAL ROLES OF ERs IN PHYSIOLOGY AND 
DISEASE 
Estrogens acting through ERs exert effects on multiple organs. Epidemiological and 
retrospective studies have provided important evidence for the diverse roles of 
estrogens in human physiology and disease. There are gender differences in 
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occurrence of several diseases. A role of estrogens in these syndromes is evident 
from the effects of menopause, when estrogen levels decrease, and estrogen 
replacement therapy. Furthermore, identification of phenotypes of ERα, ERβ, and 
ERα/ERβ knockout (αERKO, βERKO, αβERKO) mice is in many cases consistent 
with observations in humans and has provided an added molecular understanding of 
the function of ERs. 
 
UTERUS 
In the uterus, ERα is the predominant isoform, and its presence is necessary for 
reproductive functions (Couse and Korach, 1999; Matthews and Gustafsson, 2003). 
Indeed, mice null for ERα are infertile in contrast to ERβ KO mice (Hewitt and 
Korach, 2003) due in part to the failure of the uteri to develop properly (Couse et al., 
1995). Conversely, the unopposed activity of uterine ERα promotes the development 
and progression of endometrial cancers in humans and animal models (Di Cristofano 
and Ellenson, 2007). Multiple mechanisms underlie the control of ERα expression 
and activity; these include regulation at the levels of transcription involving multiple 
promoters (Kos et al., 2001); alternative splicing (Heldring et al., 2007); post 
translational modifications via phosphorylation, acetylation, and polyubiquitination 
(Atsriku et al., 2009; Fu et al., 2004; Masuyama and Hiramatsu, 2004); and post 
transcriptional silencing by micro-RNA targeting (Castellano et al., 2009). The afore 
mentioned complex regulation of ERα occurring at many levels predicts that 
perturbations in any or all of these mechanisms will lead to reproductive 
dysfunctions and diseases. 
Estrogen induces the expression of membrane receptor tyrosine kinase ligands, 
epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) in the mouse 
uterus. In addition, estrogen treatment results in activation of the IGF-I receptor 
signalling pathway (Richards et al., 1996). When IGF-I knockout mice are treated 
with estradiol, uterine epithelial cells do not undergo mitosis, indicating that 
activation of the IGF-I pathway is necessary for this uterine response to estrogen 
(Adesanya et al., 1999). Conversely, EGF or IGF-I administered in an exogenous 
dose can induce estrogen-like responses, such as epithelial mitogenesis, induction of 
estrogen target genes and increase in uterine mass (Nelson et al., 1991; Ignar-
Trowbridge et al., 1992). The mechanism appears to involve ERα, as studies using 
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cells in vitro show a requirement for ERα for IGF-I or EGF to induce estrogen-
responsive reporter constructs (Ignar-Trowbridge et al., 1992; Ignar-Trowbridge et 
al., 1993). These studies have led to a model of ‘cross-talk’ in which growth factor 
receptor activation results in maintenance, amplification or induction of ER 
transcriptional activity even in the absence of circulating estrogens. αERKO mice 
were treated with IGF-I and EGF to determine whether ERα is required for uterine 
responses to these growth factors. In both cases, the necessary membrane growth 
factor receptors were present and activated by the treatment (Curtis et al., 1996; 
Klotz et al., 2002). In addition, cfos was induced by EGF in the αERKO, indicating 
that the EGFR signaling pathway was fully functional. However, no thymidine or 
bromodeoxyuridine incorporation was induced, indicating that the EGF and IGF-I 
did not induce a mitogenic response (Curtis et al., 1996; Klotz et al., 2002), and 
therefore that this response requires ERα. Studies using ovariectomized mice 
containing an estrogen-responsive luciferase reporter transgene indicated that IGF-I 
could induce luciferase activity in the uterus in the absence of estrogen (Klotz et al., 
2002), demonstrating that the IGF-I treatment results in activation of ER 
transcriptional activity in vivo. 
 
BREAST 
ERβ is found in both ductal and lobular epithelial and stromal cells of the rodent. 
ERα, on the other hand, is only found in the ductal and lobular epithelial cells and 
not in stroma (Gotteland et al., 1995). It is generally believed that breast tumors 
depend, at least initially, on the stimulatory effects of estrogens; however, many 
breast tumors eventually progress to an estrogen-independent growth phenotype. 
Various ER transcripts have been found in breast carcinomas (Gotteland et al., 1995). 
Normal and cancer tissues display a variety of distinct profiles regarding ERα, ERβ, 
and splice variants at both mRNA and protein levels (Poola and Speirs, 2001). This 
heterogeneity in ER isoform profiles is suggested to result in variations in estrogen 
signaling and might affect breast cancer risk, hormone responsiveness, and survival. 
Some data suggest that the ERβ transcript is down-regulated in breast tumorigenesis, 
and other studies show regulation of ERβ expression by promoter methylation (Iwao 
et al., 2000; Zhao et al., 2003). Since promoter methylation is frequently observed in 
cancer (Garinis et al., 2002), these data suggest that ERβ is a possible tumor 
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suppressor gene. In vitro studies indicated that ERβ is an important modulator of 
proliferation and invasion of breast cancer cells, thus supporting the hypothesis that 
the loss of ERβ expression could be one of the events leading to breast cancer 
development (Lazennec et al., 2001) However, this hypothesis needs to be 
confirmed, because it has been shown that ERβ is expressed in the majority of breast 
tumors, with immunohistochemical staining in approximately 2/3 of breast tumors, 
similar to the percentage of tumors that express ERα. Currently, only the ERα form 
is clinically measured for clinical decision making and treatment. 
 
THE CARDIOVASCULAR SYSTEM 
As in most tissues studied, estrogen activates multiple molecular signaling pathways 
in the cells and tissues of the cardiovascular system. Functional ERs are expressed in 
in the cardiomyocytes of the heart (Mendelsohn and Karas, 2005), in vascular 
endothelial and smooth muscle cells (SMC). In aortic SMC from diabetic rats the 
cytokine-mediated iNOS activation and the estrogen response are very different, this 
effect is associated with an interplay between ERα and ERβ, indeed in diabetic 
vascular dysfunction there is a significant change in ERα and ERβ relative content. 
In vitro transfection experiments show that ER is indispensable to E2 regulation of 
iNOS transcription. There is an evidence for a direct interaction of estrogen with the 
iNOS promoter (Miller et al., 1996), which lacks canonical estrogen responsive 
elements. As proposed for the effect of estrogens on other molecules of the 
inflammatory cascade, it is conceivable that iNOS mRNA synthesis is controlled by 
ERs by interaction with transcription factors such as NF-kB, AP-1, or STATs (Xie et 
al., 1994; Faulds et al., 2001). Considering a differential effect of the two ER 
subtypes on iNOS expression, Maggi et al., (Maggi et al., 2003) proposed that the 
altered ERα/ ERβ ratio reported for diabetic SMC, and in particular the remarkable 
upregulation of ERβ, underlies the loss of E2 negative control on iNOS activity. ERα 
and ERβ expression is increased in diabetic compared with control SMC, with a 
relative increase in ERα and ERβ protein levels of 1.4- and 2.5-fold, respectively. 
The increased ERβ expression is associated with the defective response to E2 and to 
cytokines observed in diabetes; studies in ERβ-deficient mice describing an 
important role for this receptor in regulating blood pressure and vascular function 
(Zhu et al., 2002). The authors showed that ERβ is involved in estrogen-induced 
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accumulation of iNOS protein in aortic endothelium as well as iNOS gene 
transcription in normal vessels. This lends support to the view that the altered 
estrogenic control of iNOS function in diabetic SMC is mediated mainly by isoform 
beta of estrogen receptor. 
The observation that ERα and ERβ protein content is regulated by E2 in an opposite 
fashion in aortic SMC provides evidence for the potential divergent effects of the two 
receptors (Paech et al., 1997; Weatherman and Scanlan, 2001). By upregulating ERα, 
E2 may enhance the protective antiinflammatory effects mediated by this receptor 
subtype in these cells while limiting potential proinflammatory effects with ERα 
downregulation.  
Other intriguing mechanism of action of ligand-activated ERs has been studied for 
many years: the ability of ERs to signal rapidly, in an apparently non-nuclear 
manner, resulting in downstream activation of specific kinases and their effector 
molecules (Mendelsohn, 2000). Rapid, non-nuclear ER signaling in the 
cardiovascular system has been best studied in ECs, where estrogen and ERs lead to 
the rapid activation of eNOS, production of nitric oxide, and vasodilation 
(Mendelsohn, 2000). Over the past 15 years, a number of laboratories have explored 
the molecular events in this fascinating pathway in vascular ECs, in which a 
subpopulation of ERs localized to cell membrane–based caveolae (small 
invaginations of the cell membrane) mediate rapid (15–30 minutes), estrogen 
induced activation of eNOS via a pathway involving activation of the low-molecular 
weight G protein, the tyrosine kinase src, and the serine/threonine kinases Akt and 
MAPK. ERs localized to EC caveolae directly bind to a scaffold protein called 
striatin, which also binds to caveolin-1, the major structural protein of caveolae; 
striatin is required for estrogen-ER activation of the rapid, non-nuclear signaling 
pathway (Qing et al., 2004). 
 
SKELETAL SYSTEM 
Among the estrogen target organs, bone has recently drawn increasing attention 
because postmenopausal osteoporosis induced by estrogen deficiency has emerged as 
the most widely spread bone/joint disease in developed countries. Osteoporosis in 
women and men is currently considered a serious disorder of middle-aged and 
elderly people because of increased risk of bone fracture, often leading to long-term 
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incapacitation and mortality (Klotz et al., 2002; Ebeling, 2008). Pronounced bone 
mass decrease due to enhanced or imbalanced bone resorption vs. bone formation 
(high bone turnover) is a typical osteoporotic feature in women with estrogen 
deficiency or impaired estrogen signaling. The osteoporotic bone phenotype can be 
experimentally recapitulated in female rodents by ovariectomy (OVX) and 
consequent estrogen depletion (Harada and Rodan, 2003; Harman, 2006).  
Genetically modified models showed that also in the case of bone cells NO signalling 
is relevant. NO can have both direct effects on cell signaling as well as indirect 
actions mediated by the reaction products formed when NO interacts with other 
molecules, such as oxygen or superoxide, thereby playing a central role in the 
pathophysiology of inflammation and oxidant stress (Nathan, 1992; Payne and 
Kubes, 1993). iNOS, contrary to what is known for endothelial NOS (eNOS), is not 
expressed constitutively in the bone of adult mice, but was shown to be induced in 
osteoblasts and bone marrow by stimulation with proinflammatory cytokines or 
endotoxin; iNOS is apparently not required for normal trabecular bone development. 
The absence of iNOS becomes crucial when bone loss is induced by estrogen 
depletion, suggesting a predominant role of this enzyme in the osteoporosis 
consequent to deficient ovarian function. Cuzzocrea et. al., (Cuzzocrea at. al, 2003) 
suggested a relevant role for iNOS in osteoporosis in agreement with studies carried 
out on two different models of osteoporosis. 
Armour and colleagues (Armour et al., 2001) demonstrated that iNOS is 
indispensable for the development of osteoporosis consequent to systemic 
inflammation and proposed that the reduced bone formation mediated by iNOS is 
due to the dramatic increase in osteoblast apoptosis. Watanuki and colleagues 
(Watanuki et al., 2002) showed that the decreased bone volume induced by tail 
suspension is not observed in iNOSKO mice and suggested that the iNOS 
synthesized in osteoblasts plays a critical role in increasing osteogenic activity in 
response to the acute increase in mechanical loading after tail suspension.  
Cuzzocrea’s study pointed to a strong role for iNOS in osteoclast activation after 
ovariectomy. In smooth muscle cells prolonged exposure to a medium deprived of 
estrogens by itself is a stimulus sufficient to induce iNOS synthesis (Zancan et al., 
1999). In line with this observation, with ovariectomy the prolonged absence of 
estrogens causes a depression of iNOS synthesis in osteoblasts. Osteoblasts express 
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ERs ( Windahl et al., 2000; Bonnelye et al., 2001), and it is conceivable that the 
circulating levels of estradiol maintain the receptors in a state of activation sufficient 
to repress transcription of the iNOS promoter. Sequence analysis of the mouse iNOS 
promoter does not reveal any estrogen responsive element; however, this promoter 
contains NF-kB and activating protein1-responsive elements. Estradiol can modulate 
the activities of promoters controlled by these two transcription factors, it is possible 
that in the presence of estradiol the ER impairs their positive action on inos gene 
transcription. The absence of the hormone would release the ER inhibitory influence, 
with consequent pathological increase of iNOS production. 
In osteoblasts, an increased iNOS content may lead to local accumulation of nitrites 
and other products of the inflammatory cascade, which trigger osteoclastogenesis, or 
alternatively, the NO produced by osteoblasts may also activate p21 ras activity in 
the monocytes and the NF-kB signal transduction pathway necessary for osteoclast 
differentiation. The study also showed that after estrogen depletion the plasma levels 
of NO are significantly increased; as it is well known that eNOS is positively 
regulated by estrogens, this increase could be ascribed to a deficit of the estrogen 
negative control on the expression of the smooth muscle cell iNOS. Interestingly, the 
authors demonstrated that iNOS contributes to the increased expression of the 
cytokines IL-6, IL-1β and TNFα consequent to estrogen deprivation. IL-1, IL-6, and 
TNFα are known to be potent stimulators of bone resorption. In the absence of an 
appropriate stimulus such as estrogen depletion iNOS does not have any influence of 
the systemic synthesis of proinflammatory citokines. These cytokines play an 
important role in the induction of osteoclastogenesis and bone loss after estrogen 
depletion. The secretion of both IL-1 and TNFα by peripheral blood monocytes is 
increased in postmenopausal women (Pacifici et al., 1991), moreover the release of 
these cytokines can be strongly reduced by iNOS inhibition in shock (Joshi et al., 
1996; Kengatharan et al., 1996; Wang et al., 1999). The data suggested that iNOS is 
in part responsible for bone erosion in ovariectomyzed models, but also that the 
induction of NO synthesis is a key event in the subsequent activation of 
inflammatory cascades after estrogen depletion. NO can have both direct effects on 
cell signaling as well as indirect actions mediated by the reaction products formed 
when NO interacts with other molecules such as oxygen or superoxide (Kimble et al., 
1996). ROS and peroxynitrite produce cellular injury and necrosis via peroxidation 
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of membrane lipids, protein denaturation, and DNA damage. ROS produce strand 
breaks in DNA that trigger energy-consuming DNA repair mechanisms and activate 
the nuclear enzyme PARS, resulting in the depletion of its substrate NAD in vitro 
and a reduction in the rate of glycolysis. 
NAD depletion leads to a rapid fall in intracellular ATP. This process has been 
termed the PARS suicide hypothesis (Szabo and Dawson, 1998). There is an 
evidence that the activation of PARS may also play an important role in 
inflammation (Szabo et al., 1997; Cuzzocrea et al., 1998). The research demonstrated 
that absence of the inos gene attenuates the increase in PARS activity caused by 
estrogen deprivation. Thus, they proposed that iNOS induction is also important, at 
least in part, for the activation of PARS. This enzyme plays a role in the bone erosion 
after estrogen depletion. Accumulating clinical observations and genetic studies 
show that male patients defective in either estrogen biosynthesis or function of 
estrogen receptor α (ERα) display typical pathological conditions of osteoporosis 
(Smith et al., 1994; Jones et al., 2006). Thus, it is evident that estrogens exert 
osteoprotective actions and play a significant role in skeletal maintenance in both 
sexes. The first conventional gene disruption of the mouse ERα locus was achieved 
in the early 1990s (Couse and Korach, 1999). Paradoxically, however, neither males 
nor female ERα-deficient mice exhibited typical osteoporotic bone phenotypes 
(Couse and Korach, 1999; Windahl et al., 2002). Thereafter, the role of ERs in bone 
health remained obscure. Instead, indirect mechanisms via extraskeletal tissues have 
been postulated to account for the osteoprotective actions of estrogen (Zaidi, 2007; 
Pacifici, 2008). It appears that in females, osteoclastic ERα mediates estrogen 
dependent attenuation of bone resorption through stimulation of apoptosis in 
osteoclasts. Although primary cultured bone cells from males and females equally 
respond to estrogen, the osteoclast-selective ablation of ERα in male mice caused 
neither bone defects nor unclosed epiphyses (Nakamura et al., 2007) that had been 
consistently observed in male patients with impaired estrogen signaling ( Smith et 
al., 1994; Jones et al., 2006). This discrepancy suggests sex specificity in 
mechanisms of osteoprotective action of estrogens in vivo and raises a hypothesis 
that in male bones, beneficial effects of estrogens are predominantly mediated by the 
osteoblastic ERα, rather than through the antiresorptive action of osteoclastic ERα, 
which is more critical in females. This idea can be tested by cell type-specific 
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ablation of ERα in males as well as in females to decipher molecular and cellular 
mechanisms of the anabolic action of estrogens in the skeleton. At the same time, a 
compensatory action of AR at high concentrations of circulating testosterone may 
account for different physiological consequences of osteoclast-targeted ERα ablation 
in male mice.  
 
ENDOCRINE SYSTEM 
The most powerful but indirect indicator that estrogens display antidiabetic action 
comes from the observation that the overall prevalence of diabetes is lower in 
premenopausal women, a trend that is reversed after menopause (Wild et al., 2004). 
The hypothesis that this gender dimorphism is partially related to β-cell function 
stems from the observation that it is more pronounced in syndromes with severe 
insulin deficiency. Indeed, common autoimmune diseases usually show a female 
predominance except for type 1 diabetes mellitus (T1DM) (Beeson, 1994). T1DM is 
characterized by a male predominance in populations of European origin (ratio 1.7) 
(Gale and Gillespie, 2001). More interestingly, the male predominance develops after 
puberty, whereas puberty is associated with a decreased incidence in girls (Blohme et 
al., 1992). In adults, the best example of sex dimorphism is that of ketosis-prone 
diabetes (also called idiopathic diabetes, characterized by a propensity to acute 
insulin deficiency) (Mauvais-Jarvis et al., 2004). In ketosis-prone diabetes, male 
predominance is high (75%) and women are protected unless they are in a 
hypoestrogenic state (Mauvais-Jarvis et al., 2004; Louet et al., 2008). Together, the 
observations described above in diabetic syndromes with insulin deficiency suggest 
that the ovarian hormones, and especially estrogens, are protective against β-cell 
apoptosis and insulin deficiency. The antidiabetic actions of estrogen were confirmed 
in two large, randomized, double-blind, and placebo-controlled trials. The Women’s 
Health Initiative study, which included more than 15,000 women, showed a 20% 
decrease in the incidence of diabetes in the estrogen replacement therapy (ERT) 
group at 5 yr (Margolis et al., 2004). More impressively, the Heart and 
Estrogen/Progestin Replacement Study, which focused on 3000 women with a 
predisposition to oxidative stress and coronary heart disease, and thus at high risk of 
developing type 2 diabetes mellitus T2DM, resulted in a 35% reduction in the 
incidence of diabetes in the ERT group at 4 yr (Kanaya et al., 2003). Because 
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hyperglycemia cannot develop without β-cell failure, the observation that ERT 
prevents diabetes suggests that estrogens improve β-cell function or survival via 
direct or indirect mechanisms. In fact, 14 studies assessed the effect of ERT on β-cell 
function in postmenopausal women. More than half of them have reported an 
improvement in glucose-stimulated insulin secretion. Early studies suggested that E2 
administration to cultured rat islets had limited effects on insulin release (Costrini 
and Kalkhoff, 1971; Sorenson et al., 1993). More recent data from cultured mouse 
islets indicate that E2 increases islet insulin content and secretion (Alonso-Magdalena 
et al., 2008). However, the most promising and direct effect of E2 on islets is to 
enhance survival. E2 protects against oxidative stress and proinflammatory cytokines 
induced apoptosis (Contreras et al., 2002; Eckhoff et al., 2003; Eckhoff et al., 2004; 
Le May et al., 2006). ERα and ERβ are expressed in rodent and human β-cells. 
Although they can be found in the nucleus, they exhibit a predominant 
extranuclearlocalization (Nadal et al., 2000; Le May et al., 2006; Alonso-Magdalena 
et al., 2008; Liu et al., 2009). Mouse and human islets express both the long 66-kDa 
isoform and a shorter 58-kDa isoform, whereas mouse clonal β-cells express only the 
long 66-kDa isoform (Le May et al., 2006). E2-activated ERα prevents islet apoptosis 
via an estrogen response element- independent pathway in mouse and human islets. 
This is mediated via activation of extranuclear and perhaps membrane forms of ERα. 
ERα and ERβ both favour survival with a predominant ERα effect (Liu et al., 2009). 
Although the precise signalling pathways are still under investigation, ERs prevent 
apoptosis independently of gene transcription or de novo protein synthesis, 
suggesting that this cytoprotection happens independently of nuclear events (Liu and 
Mauvais-Jarvis, 2009). In cultured human islets, Contreras and co-workers 
(Contreras et al., 2002; Eckhoff et al., 2004) reported that E2 inhibits the nuclear 
factor- kB and the stress activated kinase, c-Jun N-terminal kinase. ERα is also 
important to insulin transcription. Exposure to physiological concentrations of E2 
increased β-cell insulin gene expression, insulin content, and insulin release via an 
ERα-dependent mechanism involving Src and ERK kinases (Alonso-Magdalena et 
al., 2008). Thus, the elevation in serum E2 concentration during pregnancy may 
participate to the islet adaptation to the increased metabolic demand. The effect of E2 
on β-cell proliferation in vivo is poorly studied. In one study, E2 promoted β-cell 
hypertrophy but no expansion of the β-cell population, which improved diabetes in 
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partially pancreatectomized rats (Zhu et al., 1998). In another study, E2 treatment 
increased β-cell proliferation in ovariectomized rats (Choi et al., 2005). In STZ-
challenged, hyperglycemic mice, E2 treatment did not induce β-cell proliferation (Le 
May et al., 2006), and there was no effect of E2 on β-cell proliferation in cultured 
islets (Alonso-Magdalena et al., 2008). 
Ten years ago, Nadal et al. (Nadal et al., 1998; Nadal et al., 2000) reported the 
existence of a membrane G protein-coupled receptor in β-cells unrelated to ERα and 
ERβ, which was probably GPR30. A more recent report has revealed that GPER-
deficient mice display altered E2-stimulated insulin release from isolated islets 
associated with impaired glucose stimulated insulin secretion in vivo (Martensson et 
al., 2009). Liu et al. found that elimination of GPR30 predisposes to STZ-induced 
islet apoptosis in female mice and that pharmacological activation of GPR30 by a 
selective agonist, G1, prevents oxidative stress-induced apoptosis in cultured mouse 
and human islets (Liu et al., 2009). Thus, GPR30 is important to E2 effects on islet 
function and survival. 
 
IMMUNE SYSTEM 
In postmenopausal women changes in the immune system have been attributed to 
estrogen deprivation. There is an increase in pro-inflammatory serum markers (IL1, 
IL6, TNF-alpha), an increasing response of the body’s cells to these cytokines, a 
decrease in CD4 T and B lymphocytes and in the cytotoxic activity of NK cells. Thus 
attenuated immune response and higher susceptibility to microbial invasion and 
infection are characteristic in postmenopausal women. In addition, IL-6 has been 
related to bone resorption by osteoclast activation and also seems to be associated 
with other diseases that occur more often in menopause such as diabetes, 
atherosclerosis and cardiovascular disease. IL7 is another cytokine that might be 
associated with IL-6 and bone turnover but more studies are needed previously to 
drawn definitive conclusions. Epidemiological and clinical studies indicate a positive 
action on cellular immune response of hormonal replacement at menopause, thus 
being a potential influence on the development and course of autoimmune disorders. 
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Lymphocyte 
Estradiol can modulate lymphocyte cytokine production, cytokine receptor 
expression, and activation of effector cells (Salem, 2004; Pernis, 2007; Karpuzoglu 
and Zouali, 2009). ERα is expressed in most immune cells both at baseline and at 
increased levels after estrogen administration (Rider et al., 2006; Stygar et al., 2006; 
Inui et al., 2007). It can be detected in thymocytes, bone marrow non hematopoietic 
cells, T cells, B cell precursors, and circulating B cells (Haruki et al., 1983; Stimson, 
1988; Kawashima et al., 1992; Smithson et al., 1995; Igarashi et al., 2001; Shim et 
al., 2006). One recent study examined ERα expression in resting and activated 
PBMC subsets and found that ERα was expressed at higher levels in CD4+ T cells 
than B cells. Instead, B cells expressed high levels of estrogen receptor beta (ERβ). 
CD8+ T cells expressed both ERα and ERβ at low, but equivalent levels (Phiel et al., 
2005). Since multiple studies have demonstrated estradiol responsivity of immune 
cells, one could infer that T cells would mediate this response via ERα, whereas B 
cells would respond via ERβ. The functional differences between ERα and ERβ are 
as yet unclear, but these data suggest that immune cells have the ability to respond to 
estradiol or alternative ligands with potentially disparate effects on T cells versus B 
cells due to variance in expression of ERs. 
Thurmond et al. provided evidence that, while ERα is required for regulating the 
number of B cells reaching maturity, it is not essential for maintaining the normal 
proportion of hematopoietic progenitors (Thurmond et al., 2000). 
Less is known regarding effects of ERα on T cells, however, a number of studies 
have established a role for estrogen and ERα in the thymus and early T cell 
development. For example, estrogen can cause thymic atrophy (reduction in size and 
cellularity) (Rijhsinghani et al., 1996; Okasha et al., 2001), and this effect is ERα-
dependent (Staples et al., 1999). Estrogen also influences the production of 
CD4+CD8+ double positive cells, which requires both ERα and ERβ (Erlandsson et 
al., 2001). 
Unlike B cells, estrogen effects on the T cell repertoire selection and eradication of 
autoreactive T cells has not been studied in detail. More is known about the effect of 
estrogen on mature T cells and, as with B cells, it is quite complex. Multiple studies 
have shown a role for estrogen in influencing T helper responses (Th1 vs. Th2) and 
the effect appears to be dose-dependent, i.e., low doses of estrogen stimulate a Th1 
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response and higher doses promote a Th2 response (Bebo et al., 2001; Maret et al., 
2003; Delpy et al., 2005). In vivo, estrogen administered to ovariectomized female 
mice resulted in increased antigen-specific CD4+ T cell responses and in the 
selective development of interferon-gamma (IFNγ)-producing cells. Using ERα−/− 
mice, the researchers went on to show that ERα in the hematopoietic compartment 
was necessary for this enhanced Th1 cell responsiveness. Estrogen also stimulates 
the production of regulatory T cells. Tai et al. (Tai et al., 2008) observed that ERα is 
expressed in CD4+CD25− T cells and that physiologic doses of estrogen increased 
expression of Foxp3 and IL-10 genes in vitro, as well as converted T cells from 
CD4+CD25−into CD4+CD25+ T cells indicating a role for ER. In the experimental 
autoimmune encephalitis (EAE) animal model for MS, ERα is required for the 
protective effect of estrogen (Polanczyk et al., 2004). The ability of estrogen to 
protect against EAE correlated with its ability to up-regulate FoxP3, and was 
dependent on Erα. Estrogen induced the expression of FoxP3 and potentiated the 
regulatory activity of CD4+CD25+ T cells. The ability of estrogen to protect against 
EAE correlated with its ability to up-regulate FoxP3, and is dependent on ERα. 
Dendritic cells 
Dendritic cells (DCs) are potent antigen presenting cells (APCs) that capture antigens 
and stimulate immune responses by naïve T cells. DCs not only initiate T cell 
responses, but also influence the nature of those responses (Th1 vs. Th2), as well as 
maintenance of self-tolerance. Data from multiple studies suggest that DCs and other 
APCs are modulated, both in number and function, by sex steroids, most notably 
estradiol (Hoek et al., 1997; Saito et al., 1998; Salem et al., 2000; Medina et al., 
2001; Wira et al., 2002; Nalbandian and Kovats, 2005). In vivo, APC number and 
function are also variable with different estrogen levels in the female rat reproductive 
tract (Prabhala and Wira, 1995). Consistent with this, both ERα and ERβ are 
expressed in most APCs including macrophages, monocytes, and DCs, as well as DC 
progenitors (Komi and Lassila, 2000; Sapi et al., 2002; Mor et al., 2003; Paharkova-
Vatchkova et al., 2004; Mao et al., 2005; Harkonen and Vaananen, 2006; Carreras et 
al., 2008), however, as with most cell types, there appears to be differential 
regulation of ERα vs. ERβ. For example, in murine ex vivo cultures of DCs, ERα is 
expressed in both major subsets of CD11c+ cells whereas ERβ is expressed in only 
one of the two (Mao et al., 2005). This may provide a basis for the differential 
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regulation of these two DC types by estrogen; they exhibit distinct phenotypes with 
respect to capacity for co-stimulatory molecule and MHC expression, and antigen 
internalization. In contrast, Komi et al. used blood from healthy human subjects to 
isolate PBMCs for culture, and found that immature and mature DCs expressed both 
ERα and ERβ mRNA regardless of their developmental stage (Komi and Lassila, 
2000). Estradiol promotes the differentiation of DCs from bone marrow. In a recent 
study utilizing murine bone marrow precursor cells, Paharkova et al. demonstrated 
that differentiation of DCs was inhibited in the absence of steroid hormone 
supplemented media and restored with the addition of estradiol. Additionally, DC 
differentiation was inhibited in the presence of an ER antagonist or in ERα−/− bone 
marrow cells, demonstrating a role for ERα in this process (Paharkova-Vatchkova et 
al., 2004). 
Monocytes and macrophages 
Both monocytes and macrophages are key phagocytes and provide early recognition 
of pathogens as part of the innate immune system. Their function is profoundly 
affected by the environment to which they are exposed, including not only cytokines 
and chemokines but also steroid hormones. Evidence suggests that estrogen has 
effects on monocyte and macrophage immune function. It has been known for many 
years that ERs are expressed in monocytes (Weusten et al., 1986; Suenaga et al., 
1996; Suenaga et al., 1998). However, their response to estrogen and whether ERα or 
ERβ expression dominates appears to be dependent on their stage of differentiation. 
Regulation of apoptosis is considered an important mechanism for controlling the 
number of monocytes available and therefore the intensity of the physiological 
response to infection or wound healing. Failure in the control of programmed cell 
death may become particularly relevant in tumor growth, autoimmune, and chronic 
inflammatory disorders, where apoptosis has been identified as a key factor in 
disease progression or remission (Said et al., 1997; Musgrove et al., 1998). 
Some years ago Vegeto et. al, used the premonocytic U937 cell line, which can be 
differentiated in vitro toward a macrophage-like phenotype, as a model system to 
investigate whether sex steroid hormones played a role in the manifestation of 
apoptosis. Their results suggested that both estrogen and progesterone, by interacting 
with their cognate receptor, partially prevent the onset of TNFα-induced apoptosis. 
ER and PR are expressed in U937 and can be regulated by steroid hormones, under 
 30 
 
both physiological and pathological conditions (Pacifici et al., 1991; Olsen and 
Kovacs, 1996). With this study Vegeto et al., have shown that TNFα exerts an 
antiproliferative and apoptotic activity, when physiological concentrations of 
estradiol or progesterone were added together with TNFα, 30% cells were induced to 
survive the apoptotic signal and to proliferate.  
This cellular system suggested that this effect is mediated by intracellular hormone 
receptors: 1) nanomolar concentrations of hormones are effective in inducing cell 
survival; 2) the ER antagonist ICI 182,780 is able to block estrogen activity; and 3) 
incubation of U937 cells with estrogen resulted in a decrease in Nip2 mRNA. The 
results on expression and function of the sex steroid receptors in U937 cells provide 
important informations on this cellular system and represent an interesting 
background for understanding the genetic mechanism underlying the antiapoptotic 
mechanism (Legdeur et al., 1996). The authors demonstrated that Nip-2, is regulated 
by estradiol and that encodes for a protein involved in the onset of apoptosis (Boyd et 
al., 1994), Nip-2 can be modulated by estrogen in U937 cells; this result suggests that 
the genetic pathway of response to steroid hormones is conserved among different 
cell types. Characterization of TNFα activity has shown two distinct mechanisms of 
action in induction of apoptosis by this cytokine: an initial, transcription-independent 
activity, which operates through the activation of proteases, and a subsequent 
transcription dependent antiapoptotic activity by activation of the NF-kB factors 
(Wallach, 1997). Vegeto et al., reported that interference between estradiol and 
TNFα signaling pathways occurs only when E2 is added along with or 2 h before the 
cytokine, this suggest that induction of apoptosis and/or cell survival might be 
regulated by overlapping genetic targets of TNFα and ER transcriptional activity. 
Negative interference between ER and TNFα signaling pathways has been reported 
for the interleukin-6 promoter, where transcriptional interference has been proposed 
to occur through direct physical interaction and reciprocal transcriptional silencing 
between specific members of the NF-kB family and ER. Interaction between PR and 
the NF-kB family has also been demonstrated; in addition, PR and STAT5, a 
member of the JAK/STAT family of latent transcription factors that are activated by 
numerous extracellular signals, have been shown to interact in vitro and to 
reciprocally interfere when artificially coexpressed in cells, providing further 
evidence for the hypothesis that the steroid receptors and membrane receptor-
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associated second messengers can communicate and reciprocally modulate 
transcriptional efficacy of the respective activating signals (Richer et al., 1998). The 
results of this study have provided the first evidence for receptor-mediated 
transcriptional and cellular responses of myeloid cells to estrogen and progesterone. 
After this study in 2005 Ghisletti et al. (Ghisletti et al., 2005) demonstrated that 17β-
estradiol inhibits inflammatory gene expression by controlling NF-kB intracellular 
localization, this factor has a central role in several biological pathways that govern 
immunity. The Ghisletti’s study showed that E2 prevents inflammatory gene 
transcription induced by inflammatory agents by inhibiting NF-kB intracellular 
transport, an immediate-early event in the inflammatory signaling cascade. This is a 
novel mechanism in the control of NF-kB activation that is not shared by 
conventional anti-inflammatory drugs. In addition, they showed that the effect of E2 
on NF-kB is mediated by the intracellular receptor ERα through a non genomic 
signaling pathway that involves the activation of PI3K. This discovery was the first 
report showing an inhibitory effect of E2 on the intracellular transport of proteins 
toward the nucleus. Ghisletti et. al., showed that the decreased activity of p65 
induced by E2 is due to the cytoplasmic sequestration of this transcription factor. NF-
kB activation requires the degradation of its inhibitory protein, Ik-B; NSAIDs that 
are inhibitors of NF-kB activation mediate this effect by blocking IKK activity and 
thus suppressing Ik-Bα phosphorylation and degradation. In this way, NF-kB 
remains inactive in the cytoplasm in association with Ik-B proteins. In contrast to this 
mechanism, the Maggi’s laboratory observed that inhibition of NF-kB nuclear 
accumulation by E2 occurs through the blocking NF-kB intracellular transport 
without affecting Ik-Bα degradation. It has been shown that NF-kB may utilize 
microtubules as cytoskeletal tracks to massively migrate from the cytoplasm to the 
nucleus in response to inflammatory signals. The study, also, showed that the effect 
of E2 is specific for macrophages. The action of E2 in inflammation requires the 
activation of a specific intracellular receptor. By showing that ERα mediates the 
inhibition of NF-kB transport, Ghisletti provided the mechanism to explain this 
receptor-specific anti-inflammatory activity. The effect of E2-activated ERα on NF-
kB involves a non genomic signaling pathway. Moreover, the authors demonstrated 
that the action of E2 fails when the hormone and LPS are added at the same time, 
demonstrating that the target of hormone action is the early-phase activation of LPS 
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signaling. Phosphoinositides in the plasma membrane, including PIP3, play critical 
roles in regulating the interplay between cytoskeleton dynamics and cell reactivity 
and shape in response to extracellular signals. The study showed that E2 rapidly 
stimulates the production of PIP3 in macrophages and that this induction uncouples 
the inflammatory signaling to the transport system of NF-kB. In light of the 
widespread biological responses regulated by PIP3, their results suggested that E2 
may be a master regulator of intracellular pathways activated at the plasma 
membrane of inflammatory cells by lipid secondary messengers. This notion also 
leads the authors to speculate on whether the action of the hormone on PIP3 
signaling pathways may be compromised in inflammatory-based pathologies that do 
not benefit from E2 action. The relevant and unique role played by E2 in 
inflammation may reflect the endocrine activity of this hormone, which could act as 
a protective agent against inflammatory insults in order to favor pregnancy and grant 
offspring sustenance during a woman’s fertile life. At menopause, the development 
of chronic degenerative diseases, such as those affecting bone, vessel walls, or the 
brain, is strictly associated with an increased proinflammatory reaction, indicating 
that E2 deprivation may indeed facilitate the onset of chronic inflammatory reactions. 
In summary, the Ghisletti’s finding of a novel mechanism of E2 action in 
inflammation supports the unique role of E2 in the control of innate immunity . 
 
ERs IN THE BRAIN 
For a long time the presence of ERs was ascribed in hypothalamic and preoptic area, 
to regulate endocrine functions and sex related behavior.  
In the late 1980’s several studies showed that estrogens and progesterone were 
involved also in the modulation of functions not strictly related to endocrine control, 
indeed, it was demonstrated that these hormones partecipate in the control of motor 
areas and limbic areas. Maggi and Perez, in 1984, on this postulate found that 
receptors for progesterone and estrogens are present in numerous extrahypothalamic 
brain regions, this finding had given a new impulse to studies estrogens regulation of 
brain functions (Maggi and Perez, 1984). A recent study of Maggi’s laboratory (Stell 
et al., 2007), demonstrated that ERs localized in both reproductive and non 
reproductive areas of the brain are transcriptionally active and susceptible to 
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regulation by estrogens. The study also showed, for the first time, that the extent of 
ER activity in the brain of unstimulated male and female mice is comparable and 
quite elevated (Foidart et al., 1995). This observation suggested that in brain, the sex 
hormone receptor has functions that are beyond the control of reproduction. 
Supporting this view, the activity of ER is quite sustained in males and females and 
is observed independently from the association of each given brain region to 
reproductive functions. The finding of high ER activity in male brain is not 
surprising in view of the widespread expression of aromatase in this tissue; 
furthermore, the authors believe that ligand-independent transcriptional activation of 
ER may occur, triggered by a crosstalk with growth factors and other molecules 
inducing ER phosphorylation (Ciana et al., 2003; McCaffrey et al., 2003; Maggi et 
al., 2004; Mussi et al., 2006 ;Ciana et al., 2007).  
The study clearly shows the major influence of the estrous cycle on ER activity in 
several brain areas: the effect observed in limbic areas such as the hippocampus is of 
particular interest with regard to the effects of estrogens on memory and affective 
disorders. Interestingly, ER activity in the amygdala is high in both sexes: this is 
consistent with the report that ERs are most expressed in amygdaloid nuclei. We can 
study the dynamics of ER activity with a functional method to precisely localize and 
quantify ER transcriptional activity in mouse brain, enabling the quantitative 
measurement of luciferase activity in selected brain regions created in our laboratory. 
The method can be easily expanded to the study of brain activity of transcription 
factors, protein–protein interaction, or neural cell differentiation or migration, on 
availability of the suitable reporter animals.  
ERα is generally expressed in the hippocampus, preoptic area, and most of the 
hypothalamus, the bed nucleus of stria terminalis, the ventromedila nucleus and the 
posterodorsal part of the medial amygdala, whereas it is sparse or absent from the 
cerebral cortex and cerebellum. ERβ is widely distributed in cell nuclei within 
selected regions of the brain including the olfactory bulb, cerebral cortex, septum, 
preoptic area, bed nucleus of the stria terminalis, amygdala, paraventricular 
hypothalamic nucleus, thalamus, ventral tegmental area, substantia nigra, dorsal 
raphe, locus coeruleus, and cerebellum. Extranuclear immunoreactivity is detected in 
several areas including fibers of the olfactory bulb, CA3 stratum lucidum, and CA1 
stratum radiatum of the hippocampus, the presence of hormonally regulated ERs has 
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also been found in glial cells, in microglia, and in neural stem cells (Couse et al., 
1997; Shughrue and Merchenthaler, 2001) Expression of ERs has also been observed 
in other cell types within the CNS that participate in the inflammatory reaction, 
namely endothelial cells and circulating leukocytes (Vegeto et al., 2003). Cerebellum, 
hippocampus and the amygdala, are regions responsible for anxiety, depression, and 
learning and memory, ERβ has key role in these regions but also in the serotonergic 
neurons of the dorsal raphe nucleus (DRN) in the midbrain. The DRN is the primary 
part of the midbrain housing serotonergic cell bodies that project to other parts of the 
brain. In postmenopausal women serotonergic activity is low and can be increased by 
administration of E2 (Halbreich et al., 1995). E2 influences several aspects of 
serotonin function: release, metabolism, reuptake, synthesis and receptor 
modification (Osterlund, 2009). With this profound influence of E2 on the 
serotonergic system it is not surprising that ovariectomy, menopause, antiestrogen 
treatment, GnRH analog treatment, and postpartum and premenstrual periods are 
associated with depression (N-Wihlback, 2006). It is also easy to understand why 
selective serotonin reuptake inhibitors (SSRIs) are effective antidepressants. 
Interestingly, coadministration of E2 (Schneider et al., 2001) or raloxifene 
(Grigoriadis et al., 2005; Sugiyama et al., 2007; Yokoyama et al., 2008) with SSRIs 
augments their antidepressant action. There is now a consensus that the DRN is ERα-
poor or ERα-negative, whereas it is strongly ERβ-positive, both at the mRNA ( Lu et 
al., 1999; Gundlah et al., 2000; Gundlah et al., 2001) and protein levels (Mitra et al., 
2003; Nomura et al., 2005; Vanderhorst et al., 2005). Although ERα and ERβ are 
coexpressed in many other regions of the brain, there is a clear segregation of the 
ERs at the level of the midbrain. ERβ was found to increase Tph2 mRNA expression 
in rat brain, and administration of a selective ERβ ligand, diarylproprionitrile (DPN), 
decreased depression-like behavior of rats (forced swim test) (Donner and Handa, 
2009). Therefore, not only is ERβ present in the DRN but it has clear functions in the 
serotonergic neurons in the DRN. In contrast to the DRN, which is ERα-negative and 
ERβ positive, many other parts of the brain express both ERs.  
Maggi and Zucchi analyzed the distribution of estrogen receptor (ER) via 
immunoenzymatic assay in the brain of ovariectomized rats and found  the presence 
of large amounts of ER-like immunoreactive material in the cytosol of the 
hippocampus: a brain area described to contain little estrogen-binding activity. The 
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protein detected in the hippocampus by the specific antibody is indistinguishable 
from the rat ER in its response to hormonal treatments and in its electrophoretic 
mobility. The presence of elevated amounts of ER in such an important part of the 
limbic system had creates new possibilities for interpreting the role played by this sex 
hormone in the central nervous system of rat. In areas such as the hippocampus, the 
amygdala and the hypothalamus, the role of E2 signaling is more complex. Maggi et. 
al. (Maggi et al., 2004), think that existence of two subtypes of ER in the same cell 
permits fine-tuning of E2 signaling; therefore, by investigating the interaction 
between the two ERs (e.g. their direct interaction and/or interactions of molecules 
downstream in their signaling pathways) they might understand some of the 
ambiguities in the physiological effects of E2. If they presume that ERα and ERβ 
have opposite effects in some situations then they can begin to explain several 
puzzling actions of E2. 
Brain functions can be broadly divided into three categories: affection (mood or 
emotion), behavior, and cognition (learning and memory). Estrogen has a strong 
influence over all three. The effects of E2 on emotion (anxiety and/or depression-like 
behavior) are inconsistent and paradoxical. Past studies report that E2 can reduce, 
increase, or have no effect on performance in several behavioral tests of anxiety 
and/or depression-like behavior (Imwalle et al., 2005; Toufexis et al., 2007). There is 
increasing evidence that ERα activation is anxiogenic (Morgan and Pfaff, 2001; 
Lund et al., 2005; Toufexis et al., 2007) whereas ERβ activation is anxiolytic (Krezel 
et al., 2001; Imwalle et al., 2005; Lund et al., 2005; Walf and Frye, 2005; Toufexis et 
al., 2007; Frye et al., 2008; Walf et al., 2008; Donner and Handa, 2009; Osborne et 
al., 2009) and/or antidepressive (Walf et al., 2004; Rocha et al., 2005; Walf and Frye, 
2007; Hughes et al., 2008; Walf et al., 2008; Donner and Handa, 2009). Thus E2 (that 
can act at both receptors) should, and does, have unpredictable effects on emotion. In 
studies of aggressive behavior, for example, ERα and ERβ show dramatically 
opposing effects. Based on the behavior of ERα_/_ and ERβ_/_ mice it has been 
suggested that ERα enhances aggressive behavior (Ogawa et al., 1997; Ogawa et al., 
1998) whereas ERβ reduces aggression (Ogawa et al., 1999; Nomura et al., 2002). 
Further, ERβ, but not ERα, is believed to enhance cognitive performance in several 
learning tasks (Frye et al., 2008; Walf et al., 2008; Osborne et al., 2009). Rissman et 
al. (Rissman et al., 2002) reported that wild-type female mice with or without E2 
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showed the same performance of spatial learning tested in the Morris water maze 
(MWM) as ERβ_/_ females. However, when ERβ_/_ females were treated with E2 
there was impaired spatial learning. These results could be interpreted to mean that, 
in the absence of ERβ, E2-activated ERα interferes with spatial learning. 
One should not try to oversimplify the role of ERα and ERβ in the brain, notably 
because anxiety and depression-like behavior are tightly connected with spatial 
learning ability and aggressive behavior, and all behaviors are also affected by sexual 
influences related to reproductive function. Furthermore, it is important to note that 
timing of the activation of ERs is crucial. For example, when neonatal mice are 
treated with the ERβ-specific agonist DPN there is increased anxiety and aggression 
during adulthood (Patisaul and Bateman, 2008). To date, despite its importance, 
information about the temporal expression of ERβ in the brain throughout life is very 
limited. If author’s hypothesis is right, all mouse experiments addressing the role of 
the two estrogen receptors should include ERαβ_/_ and aromatase knockout (ArKO; 
Cyp19a1_/_) mice because, when one observes a functional impairment in an ERa_/_ 
or ERβ_/_ mouse, it is difficult to tell whether the phenotype is due to loss of one 
receptor or to the overactivity of the receptor which remains. For example, a 
phenotype observed in ERβ_/_ mice, but not observed in ERαβ_/_ or ArKO mice, is a 
strong indication that this phenotype is caused by overactivity of ERα rather than by 
the absence of ERβ itself. Several studies suggested that estrogen increases the risk 
of gynecological tumors (Morch et al., 2009) there has been a lively debate on the 
safety of hormone replacement therapy in postmenopausal women. After the 
discovery of ERβ, and confirmation of its presence in the brain, many researchers 
raised the question of whether ERβ-specific ligands can be used as novel therapeutic 
agents with the desirable effects of estrogen but without risk of tumor incidence. The 
involvement of estrogen in pain has been demonstrated (Chakrabarty et al., 2008; 
Fan et al., 2007), and pain disorders might be treated using ERβ agonists. One study 
has shown that E2-activated ERβ dampens endogenous pain caused by increased 
nociceptive neuronal activity (Spooner et al., 2007), and another has demonstrated 
that ERβ agonists alleviate chronic but not acute inflammatory pain states (Gardell et 
al., 2008).  
ERβ is also a promising novel drug target for treatment of hypertension (HT) and 
panic disorder. Because ERβ_/_ mice are hypertensive it is possible that ERβ regulates 
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vasopressin and/or oxytocin in the magnocellular neurosecretory cells of the 
hypothalamus that are ERβ-positive but ERα-negative (Somponpun and Sladek, 
2002). Several different types of drugs with multiple targets are available for control 
of HT. However, for HT and cardiac palpitations caused by psychiatric disorders, 
such as panic disorder, no effective treatment is yet available. Depression, anxiety, 
hypertension and epilepsy, and alterations in cognition, appetite control, and pain 
threshold, are not isolated phenomena but frequently coexist. Development of 
effective ERβ-targeted drugs would probably provide significant benefits to many 
patients suffering from psychiatric disorders. 
 
INTERACTIONS OF ESTRADIOL AND INSULIN-LIKE 
GROWTH FACTOR-I SIGNALING IN THE NERVOUS 
SYSTEM 
Insulin-like growth factor-I (IGF-I) is a hormone of the somatotrophic axis and a 
local factor produced in many tissues, including the nervous system (LeRoith, 2008). 
IGF-I has pleiotropic actions in the brain and influences neuronal development, 
synaptic plasticity, neuroendocrine regulation, adult neurogenesis and cognition 
(Aberg et al., 2006; Fernandez et al., 2007; Aleman and Torres-Aleman, 2009). IGF-
I is also a potent neuroprotective molecule (Carro et al., 2001; Aberg et al., 2006). 
IGF-I is actively transported across the blood–brain barrier (Carro et al., 2006). 
Therefore, brain function is factor (BDNF) (Carro et al., 2000; Ding et al., 2006) and 
vascular endothelial growth factor (VEGF) (Lopez-Lopez et al., 2004; Lopez-Lopez 
et al., 2007). In addition, IGF-I interacts with the ovarian hormone estradiol in the 
regulation of multiple events in the nervous system. IGF-I interacts with estradiol in 
the regulation of developmental events in the nervous system. An interaction 
between these two factors may contribute to the generation of structural sex 
differences in the brain by the regulation of the survival and differentiation of 
developing neurons in brain areas involved in the regulation of neuroendocrine 
events and reproduction (Carrer and Cambiasso, 2002). 
Several studies have demonstrated an interdependence of ERs and IGF-I receptor in 
the promotion of the survival and differentiation in primary cultures of developing 
hypothalamic neurons (Duenas et al., 1996). Both estradiol and IGF-I promote 
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neuronal survival and differentiation in primary neuronal cultures grown in a defined 
medium deprived of serum and hormones. 
Different neurodegenerative conditions are associated with modifications in serum 
IGF-I levels (Busiguina et al., 2000; Carro et al., 2000). Furthermore, mice with low 
levels of serum IGF-I, as a consequence of specific targeted disruption of the IGF-I 
gene in the liver, had reduced neurogenesis in the hippocampus together with 
impaired spatial learning (Trejo et al., 2008). Moreover, the disruption of IGF-I input 
to the brain promotes amyloidosis, cognitive disturbance, hyperphosphorylated Tau 
deposits, gliosis and synaptic protein loss. This finding supports the hypothesis that 
disrupted IGF-I signalling may be involved in the pathology of Alzheimer’s disease. 
Indeed, systemic IGF-I promotes brain b-amyloid clearance, stimulating the neuronal 
release of the mmolecule and the transport into the brain of bamyloid carrier proteins 
that will take the molecule out of the brain (Carro et al., 2002; Carro and Torres-
Aleman, 2004). Therefore, decreased systemic IGF-I levels may result in an impaired 
b-amyloid clearance. In addition to the neuroprotective effects of peripheral IGF-I, 
local IGF-I produced in the nervous system may also play a role in neuroprotection. 
Brain injury induces the synthesis of IGF-I and estradiol by reactive astrocytes 
(Hwang et al., 2004; Garcia-Segura, 2008; Saldanha et al., 2009) and up-regulates 
ERs, IGF-I receptors, and IGF-binding proteins in reactive glia (Garcia-Ovejero et 
al., 2002; Chung et al., 2003). Therefore, estradiol and IGF-I released by reactive glia 
may act directly on these cells or on neighbouring neurons, regulating reactive 
gliosis, neuronal survival and the reorganization of neural tissue after injury. Indeed, 
IGF-I and estradiol interact to regulate the plastic response of the brain after injury 
and during neurodegenerative conditions. 
IGF-I promotes neuronal survival and inhibits neuronal apoptosis in vitro and in vivo 
in a variety of experimental models of neurodegeneration ( Carro et al., 2003; Trejo 
et al., 2004; Aberg et al., 2006) In vivo, IGF-I has also been shown to be a 
neuroprotective factor against a variety of neurodegenerative conditions, including 
hypoxic-ischaemic brain injury ( Guan et al., 1993; Guan et al., 2003), excitotoxicity 
(Carro et al., 2001) and cerebellar ataxia (Fernandez et al., 1998; Fernandez et al., 
1999; Fernandez et al., 2005). IGF-I neuroprotective effects are exerted by the 
activation of the main intracellular signalling pathways associated with IGF-I 
receptors, the MAPK and the PI3K/Akt pathways (Guan et al., 2003). In particular, 
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the inhibition of GSK3b activity, which is downstream of the PI3K/Akt pathway, 
seems to be an essential step in the neuroprotective mechanism (Brywe et al., 2005). 
The interaction of IGF-I and estradiol in neuroprotection has been assessed in 
ovariectomized rats in vivo, using systemic administration of kainic acid to induce 
degeneration of hippocampal hilar neurons, an experimental model of excitotoxic 
cell death. Both the systemic administration of estradiol and the 
intracerebroventricular infusion of IGF-I prevent hilar neuronal loss induced by 
kainic acid. The neuroprotective effect of estradiol is blocked by the 
intracerebroventricular infusion of an IGF-I receptor antagonist, while the 
neuroprotective effect of IGF-I is blocked by the intracerebroventricular infusion of 
the ER antagonist ICI 182780. Similar results have been obtained in ovariectomized 
rats after the unilateral infusion of 6-hydroxdopamine into the medial forebrain 
bundle to lesion the nigrostriatal dopaminergic pathway. Pre-treatment with estradiol 
or IGF-I prevents the loss of substantia nigra compacta neurons, the decrease in 
dopaminergic innervations of the striatum and the related motor disturbances. 
Blockage of IGF-I receptor by the intracerebroventricular administration of the IGF-I 
receptor antagonist JB1 attenuates the neuroprotective effects of both estrogen and 
IGF-I (Quesada and Micevych, 2004). In addition, the neuroprotective action of 
estradiol against 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) toxicity in 
the nigro-striatal system of male mice is associated to the regulation of IGF-I 
receptor signalling (D'Astous et al., 2006). These findings suggest that the 
neuroprotective actions of estradiol and IGF-I after brain injury depend on the co-
activation of both ERs and IGF-I receptor in neural cells. Furthermore, in a model of 
global cerebral ischaemia, in which both estradiol and IGF-I prevent neuronal loss in 
hippocampal CA1, simultaneous treatment with both factors do not have an additive 
effect (Traub et al., 2009). This suggests that both factors may use the same 
signalling mechanisms to exert neuroprotection. 
 
E2 AND NEUROPROTECTION 
In the last few years a clear and relevant protective role of estrogens against neural 
cell death has been delineated, as extensively illustrated by animal and cellular 
models of neurodegeneration (Behl et al., 1997; Meda et al., 2000; Bebo et al., 2001). 
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This beneficial effect of estrogens can be explained by their neurotrophic and 
antiapoptotic functions and anti-inflammatory potential. 
 
NEUROTROPHIC ACTIVITY 
Some studies propose that the trophic activities of estrogens during the maturation of 
the CNS may continue to exist in the adult brain and ensure that neurons maintain the 
synaptic connections indispensable for neural signaling and survival. Toran-Allerand 
demonstrated that estradiol treatment of explants cultures of cerebral cortex and 
hypothalamus stimulates extensive neurite outgrowth (Toran-Allerand et al., 1980). 
Since then, several studies in dissociated neurons in culture or in neuroblastoma cells 
showed that estradiol increases cell viability, differentiation, neurite outgrowth, and 
spine density and controls the ability of neurons to extend neurites and to form 
synaptic connections with other cells via dendritic spines (Maggi et al., 2004). 
Estrogens were shown to modulate the synthesis of growth factors, such as nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF), insulin-like growth 
factor-1 (IGF-1), transforming growth factor-beta (TGF-β), and related receptors, 
TrkA and TrkB, in neurons and astroglia (Cardona-Gomez et al., 2000) and this de 
novo synthesis of growth factors is required for neurite formation. 
 
ANTI-APOPTOTIC ACTION 
Estradiol protects neurons against cell apoptosis by regulating the expression of anti- 
and proapoptotic proteins, as observed in primary neuronal cell cultures, tumor-
derived neuronal cell lines, mixed neuron/astrocyte cell culture, and organotypic 
explants. Several of the known antiapoptotic genes, such as Bcl-2 and BclXL, are 
transcriptionally activated by the hormone through the classic mechanism of 
transcriptional regulation, as EREs are present in the promoter sequence of these 
genes (Garcia-Segura et al., 1998; Dong et al., 1999; Gollapudi and Oblinger, 1999; 
Pike, 1999). Accordingly, proapoptotic genes (bax, bad, bcl-Xs) are down-modulated 
by estrogens, thus indicating that the antiapoptotic activity of estradiol controls the 
balance between apoptotic and antiapoptotic genes (Patrone et al., 1999; Pike, 1999). 
In addition, estrogen acts on antiapoptotic protein activity by an indirect mechanism, 
as shown in the case of BNIP2, a protein that inactivates bcl-2 through protein- 
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protein interaction (Boyd et al., 1994), which is negatively modulated by estrogens in 
different cellular systems (Garnier et al., 1997; Vegeto et al., 1999; Meda et al., 
2000). 
 
ANTI-INFLAMMATORY POTENTIAL 
Recent data provided by in vivo and in vitro studies suggested that estrogens exert a 
protective effect against brain disorders by influencing the inflammatory response. 
This anti-inflammatory hypothesis also stemmed from the evidence that menopause, 
which is characterized by the drastic drop in estrogen levels, results in an increased 
incidence of inflammatory pathologies of brain and other tissues. 
The anti-inflammatory properties of female steroid hormones is demonstrated in vivo 
in animal models of CNS inflammation, that is, experimental autoimmune 
encephalomyelitis (EAE, the animal model of MS), brain ischemia, globoid cell 
leukodistrophy, and experimental brain inflammation. Treatment with physiological 
doses of estrogen before the onset of disease downregulates the expression of 
inflammatory factors, including cytokines, chemokines, and their receptors, (Matejuk 
et al., 2001; Matsuda et al., 2001) apolipoprotein E (Horsburgh et al., 2002), and 
other modulators of leukocyte migration, such as matrix metalloproteinase-9, 
complement receptor-3, and scavenger receptor-A50,51; moreover, estradiol strongly 
opposes the influx of leukocytes into the CNS, which is a distinctive sign of ongoing 
inflammation in these pathologic conditions (Weissman et al., 1993; Jansson and 
Holmdahl, 1998; Ito et al., 2001; Horsburgh et al., 2002). 
Both chronic or acute–traumatic brain diseases are known to be under estrogen 
control. These hormones may influence brain development dysfunctions (autism), 
neurotransporter impairments (depression, anorexia and bulimia), neurodegenerative 
diseases (Alzheimer’s disease, Parkinson’s disease, Amyotrophic lateral sclerosis), 
traumatic episodes and injuries (epilepsy and skull trauma), immune system 
dysfunctions (multiple sclerosis), and ischemic damage (ictus). 
The prominent role of estrogens in these CNS disorders has been hypothesized, and 
in some cases for a long time, based on the evidence that the incidence, course, and 
gravity of these disorders were strongly dependent on the plasma level fluctuations 
of these hormones, as it occurs during the menstrual phases, after parturition, or at 
menopause; additional indications arise from the comparison between age-matched 
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males and females in the manifestation of disease. Several examples of these 
observations are present in the literature, relating to mood disorders, (Gregoire and 
Drahmoune, 2000) psychotic episodes (Huber et al., 2001), Alzheimer’s disease 
(AD) (Henderson, 1997), Parkinson’s tremors (Tsang et al., 2000), amyotrophic 
lateral sclerosis (ALS) (Veldink et al., 2003), or ischemic insults. 
It is now well established that estrogens are involved in the control of the 
inflammatory response. The following description summarizes some examples of 
brain diseases characterized by an inflammatory reaction state, in which estrogens 
were shown to be involved by molecular, cellular, and pathophysiological evidence. 
 
ALZHEIMER’S DISEASE 
The inflammatory component plays a relevant role in this disease, in which there is a 
clear activation of the resident macrophage cell population. In human biopsies 
immunohistochemical analyses revealed a strong activation of microglia around 
senile plaques, the main pathologic feature of this disorder (Kalaria and Perry, 1993). 
Activation of microglia, increased levels of inflammatory mediators, and cells 
associated with amyloid deposition have also been observed in animal models of AD 
(Bomemann, 2001); yet, the precise role of inflammation in AD progression is still 
debated. Clinical trials involving the use of nonsteroidal anti-inflammatory drugs 
reduced the incidence of AD (Stewart et al., 1997; Anthony et al., 2000; Yip et al., 
2005). On the other hand, many studies support the idea that microglia are beneficial 
to the diseased brain (Turrin and Rivest, 2006), through the release of neurotrophic 
factors (Nguyen et al., 2002) and phagocytosis of amyloid deposits (Rogers and Lue, 
2001). The incidence of AD is higher in women than in men and the progression of 
this disease has different features in the two sexes (Barnes et al., 2005; Liu et al., 
2005). Epidemiological evidences suggest protective effects of the hormone 
replacement therapy (HRT) on the onset of this pathology and some experimental 
analyses confirmed this evidence demonstrating the prevention of cerebral structure 
degeneration by estrogens (Henderson et al., 1994; Henderson, 1997). On the 
contrary, recent clinical trials on women taking progesterone–estrogen combination 
therapy suggested an increased risk of dementia (Yaffe, 2003). Recently, a model of 
brain estrogen-deficient AD mice was generated by crossing the aromatase knockout 
mice with an AD transgenic mouse line of AD (Yue et al., 2005). Absence of the 
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enzyme for the synthesis of estrogens specifically in brain areas resulted in the early 
onset of pathology and in increased β-amyloid peptide deposition. 
 
PARKINSON’S DISEASE 
Parkinson’s disease (PD), a degenerative pathology of dopaminergic neurons 
localized in the substantia nigra pars compacta (SNc), is also characterized by the 
presence of activated microglia surrounding Lewy’s bodies, α-synuclein 
accumulation elements. Some clinical studies suggested that this neuroinflammatory 
reaction can be a critical factor for the development of this disease (Casals et al., 
1998; Ling et al., 2002). Immunological analyses of brain biopsies from PD patients 
showed the presence of activated microglia cells, with increased HLA-DR and CR3 
receptor expression, without reactive astroglyosis (Banati et al., 1998; Mirza et al., 
2000); in PD tissues, the levels of ROS, IL-1β, IL-6, and TNF-α are 
increased.(Jenner and Olanow, 1998). Frequency of PD is high in men having a ratio 
of 1:5 or 3:7 (concerning the ethnic provenience) compared to that in women, who 
show low symptom gravity and need lower doses of levodopa (Lyons et al., 1998). In 
women, pathological symptoms get worse with reduced estrogen levels during the 
menstrual cycle (Quinn and Marsden, 1986). Furthermore, symptoms seem to 
increase in women, which interrupts their HRT. Several retrospective clinical and 
epidemiological studies tried to connect estrogen treatment with onset and severity of 
the pathology. These results are discordant: some show indications of a late onset 
and a decrease in disease risk with estrogen, (Benedetti et al., 2001) whereas other 
observations show no difference in these parameters, but an amelioration in cognitive 
faculty (Marder et al., 1998; Thulin et al., 1998). Also, the prospective studies do not 
reach a definitive conclusion, as one shows that estrogens do not provide significant 
symptomatic variations (Strijks et al., 1999), while other studies indicate that 
hormone treatment reduces the levodopa dose after only 10 days of therapy 
(Blanchet et al., 1999) and that prolongs the follow-up period (Tsang et al., 2000). 
One recent clinical study demonstrated that estrogen therapy has a beneficial effect, 
establishing that women treated with estrogens have a low pathology risk than that of 
the not-treated ones (Currie et al., 2004). 
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AMYOTROPHIC LATERAL SCLEROSIS 
ALS is a neurodegenerative disease that involves primary cerebellar and spinal cord 
motorneurons. Recent studies provided evidence for the involvement of 
neuroinflammatory processes in this disease. Tissues from ALS patients show a 
widespread activation of microglia and astrocytes. In tissues, blood, or cerebrospinal 
fluid from ALS subjects there is an abundant expression of proinflammatory markers 
like TNF-α, IL-1β IL-6, IL-2, IFN-γ RANTES, and the COX enzyme. These data are 
confirmed also in animal models of mice and rats (Hensley et al., 2002; Chen et al., 
2004; Malaspina and de Belleroche, 2004; Xie et al., 2004). 
 
AGING AND MENOPAUSE 
In the developed world, mean life expectancy for women since 1900 has increased 
from 50 to 81.7 years. Particularly striking is the remarkable increase in the 
proportion of women over fifty in the population, which has tripled since the turn of 
the 19th century. Popolation projections estimated approximately 1,200 million in the 
world to be aged 50 years and older in 2030. The numbers of postmenopausal 
women in the developing world are anticipated to increase much more rapidly than 
those in the industrialized world. From 1990 to 2030 the proportion of 
postmenopausal women in more developed countries is expected to decline from 40 
to 24 percent, whereas it will increase from 60 to 76 percent in less-developed 
countries. The most profound and universal alteration in the mature aging endocrine 
system occurs in women and is due to menopause. 
Accelerated population aging has led to a major epidemiological transition in the 
leading causes of death from infections and acute diseases to the chronic and 
degenerative diseases of old age (such as malignant neoplasms cardiovascular and 
cerebrovascular diseases, osteoporosis and dementia). Now aging is appreciated as 
the eterogeneous product of a genetic disposition being revealed under varariable 
enviromental, behavioural, psychosocial, and economics conditions, many of which 
are amenable to profound change with existing as well as emerging strategies.  
Aging leads to a significant deterioration of the physiological systems, including the 
immune, nervous and endocrine systems, as well as of the immune-neuroendocrine 
network (De la Fuente, 2008). The age-related decline in immunity, known as 
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immunosenescence, involves innate and adaptive immune responses, but concerns 
especially T cell functions (Gruver et al., 2007; Kumar and Burns, 2008; De la 
Fuente and Miquel, 2009). As regards the endocrine system, aging involves a 
progressive decrease in the secretion of several hormones such as estrogens (Arlt and 
Hewison, 2004). These hormones, due to the widespread distribution of their 
receptors throughout the brain (Aloysi et al., 2006; Morrison et al., 2006), also play a 
key role in the neurobiology of aging (Morrison et al., 2006) as they exert a great 
influence on a broad array of brain regions, mostly areas associated with cognition, 
memory and emotional processing (as mood and affect). All these areas constitute 
important sites of agree-lated neurodegenerative changes, such as neuronal loss and 
compensatory gliosis (Ferrari and Magri, 2008). Other physiological age-related 
changes commonly described among the elderly include balance dysfunctions, 
reduced speed, shorter step length and muscular weakness due to skeletal mass 
reduction (El Haber et al., 2008). According to all the above, one essential concept 
that must be taken into consideration when studying the aging process is the concept 
of “biological age,” which arises as a consequence of the different rates of 
physiological changes in the members of a population of the same chronological age 
and suggests that chronological and biological age do not necessarily coincide (De la 
Fuente and Miquel, 2009). Therefore, the assessment of biological age requires the 
use of biomarkers to determine the level of senescence and life expectancy. The 
immune system has been proposed as a good marker of health, biological age and 
predictor of life span, since a good maintenance of several immune functions is 
related to a longer life span (Wayne et al., 1990; Guayerbas et al., 2002). 
Although during the last decades of the 20th century human life expectancy in 
developed countries has increased from approximately 75 to 83 years, the age at 
which women encounter their major age-related hormonal change, that is, 
menopause, has remained essentially constant at around 50 years (Miquel et al., 
2006). Therefore, many women will spend over one-third of their lives in the 
postmenopausal state. Since estrogens have a regulatory role on many organs, the 
rapid decline in their circulating levels associated to menopause triggers many 
physiopathological reactions, making women more prone to experience disease and 
disability (Amin et al., 2003). Thus, chronic deficiency of sex hormones has many 
implications in a wide variety of non-reproductive functions, and among the most 
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studied symptoms we can cite hot flashes, skin aging and high risk of osteoporosis 
and cardiovascular disease (Miquel et al., 2006). There have also been described 
different psycho-emotional symptoms that somehow overlap with depressive 
symptoms and include disturbed sleep, lack of concentration, anxiety, irritability, 
frustration, mood lability, depression and fatigue (Rasgon et al., 2005; Sarkaki et al., 
2008). Moreover, estrogens have been shown to influence the development, 
regulation and normal functions of the immune system (Islander et al., 2003; 
Rehman and Masson, 2005). These hormones modulate lymphoid cell growth, 
differentiation and proliferation, antigen presentation, cytokine and antibody 
production, NK activity and cell survival (McMurray, 2001). Thus, the repercussions 
of menopause on female health have become a subject of increasing interest. 
To tackle this question, a great deal of research has been done during the last few 
years in murine experimental models as a first approach to clarify the repercussions 
of menopause. Since rodents become anovulatory at a mature age (10–12 months 
old) but maintain a basal gonadal steroid secretion, in contrast to what happens in 
women (Nelson, 2008), ovariectomy in those animals became the best tool to mimic 
human ovarian hormone loss. Not surprisingly, during the last years there has been a 
great increase in the number of published work focusing on the consequences of 
ovariectomy, mainly in rats, on different physiological functions or systems, such as 
the central nervous system, vascular function, hepatocytes, bone, skin (Castillo et al., 
2005; Perez-Martin et al., 2005; Castillo et al., 2006; Tresguerres et al., 2008) and 
immune function (De la Fuente et al., 2004; Baeza et al., 2007; Baeza et al., 2009). 
 
DEFINITION OF MENOPAUSE 
Female reproductive senescence is a lifelong process that begins before birth and  
culminates with ovarian follicular depletion and the menopause. The word 
“menopause” (“ménopausie”) was used for the first time in 1816 by Guardanne. 
Initially, the phenomenon of menopuase was explained as a deficiency of ganglionic 
regulatory functions. In 1910, Marshall recognized that the ovary should be classified 
as an endocrine organ.The menopause results from reduced secretion of the ovarian 
hormones oestrogen and progesterone, which takes place as the fi nite store of 
ovarian follicles is depleted. Natural menopause is diagnosed after 12 months of 
amenorrhoea not associated with a pathological cause. 
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Menopause can also be induced by surgery, chemotherapy, or radiation. Initially, the 
menstrual cycle lengths become irregular, and follicle-stimulating hormone (FSH) 
concentrations rise in response to decreased concentrations of ovarian hormones. As 
the menopausal transition progresses, menstrual cycles are missed and ultimately 
stop, as does ovulation. For some women, 3 consecutive months of amenorrhoea, or 
mean cycle lengths longer than 42 days, are predictors of impending menopause 
(Dudley et al., 1998; Taffe and Dennerstein, 2002). Several terms have been used to 
describe the events that take place during the menopausal transition. A model 
developed at the Stages of Reproductive Aging Workshop (STRAW) (Soules et al., 
2001) described seven stages of reproductive ageing, which were subdivided into 
reproductive stages, characterised by regular menstrual cycles; menopausal transition 
stages, with variable menstrual cycles and high FSH values; and postmenopause 
stages, beginning with the final menstrual period, and lasting until the end of life. 
The menopausal transition usually begins when women are in their mid-to-late 40s, 
and can last several years, most commonly 4–5 years. The final menstrual period 
generallyn happens when women are between 40 and 58 years old, and a final 
menstrual period before 40 years of age is regarded as premature. The age at which 
women have their final menstrual period varies across large surveys done in different 
countries. 
For many years, the menopausal transition was viewed to be simply the end product 
of accelerated oocyte depletion. Moreover, hypothalamic-pituitary axis (HPA) 
dysfunction was thought to reflect a compensatory response to the gradual decline in 
the number and quality of remaining oocytes. However, recent studies challenge the 
conventional belief that ovarian aging is the sole determinant of when females begin 
the transition into reproductive senescence and raise questions about the sequence of 
pathophysiological events that initiate reproductive quiescence (Hall, 2007). There is 
now a convincing body of literature in primates and non-primates that support a role 
for HPA dysfunction independent of ovarian aging in the transition into reproductive 
senescence (Brann and Mahesh, 2005; Hall, 2007). Moreover, aberrant 
responsiveness of the HPA to estrogen feedback and the subsequent generation of 
abnormal patterns of gonadotropin release may in itself accelerate ovarian follicular 
exhaustion (Klein et al., 1996). Defining the physiological and cellular mechanisms 
that initiate female reproductive senescence is an area of intense scientific interest. 
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Understanding the mechanisms that propel women into the menopause may offer 
opportunities for interventions that delay menopause-related increases in disease 
morbidity and thus improve the overall quality of life for aging women. 
 
NON HUMAN MODELS OF FEMALE REPRODUCTIVE 
AGING 
Rodents are useful models for studying female reproductive physiology because they 
exhibit a high degree of genetic and physiologic similarity to humans, have a 
relatively short lifespan, and homogeneous strains are widely available at low cost 
(Wu et al., 2005). The rodent estrous cycle exhibits similar patterns of cyclic changes 
in serum LH, FSH, estradiol and progesterone levels as the human menstrual cycle. 
The primary differences are the very short luteal phase and the absence of menses 
when pregnancy does not occur in rodents. Although reproductive aging manifests 
somewhat differently in rodents andhumans (e.g., oocyte depletion does not occur 
before rodents become reproductively senescent) (Wise et al., 2002), several 
fundamental similarities are seen in perimenopausal women and middle-aged 
rodents: (1) one of the first physiological signs of impending reproductive 
senescence is elevated FSH levels (Cooper et al., 1980; Burger et al., 1996; Guthrie 
et al., 1996; Santoro et al., 1998; Anzalone et al., 2001); (2) elevated FSH is 
associated with attenuated granulosa cell production of inhibin B; (3) middle-aged 
rats (Cooper et al., 1980) and women (Weiss et al., 2004) exhibit altered 
hypothalamic-pituitary axis responsiveness to estrogen positive feedback; (4) altered 
patterns of gonadotropin secretion occur long before overt ovarian failure; and (5) 
both humans and rodents develop highly variable cycle lengths with ovarian steroid 
production preceding reproductive quiescence (Wise et al., 2002). Because so man 
ychanges in reproductively aging rodents parallel those in aging women (Hall, 2007; 
Veldhuis, 2008) investigators have used female rodents, especially rats, to explore 
the role of the HPA in the onset of female reproductive senescence. Consequently, 
much of what we know about the HPA and female reproductive aging is derived 
from studies in rats and mice (Downs and Wise, 2009). 
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MODEL SYSTEMS TO STUDY ER PHYSIOLOGICAL 
ACTIVITIES 
In the last twenty years the use of cell systems and engineered cells has tremendously 
aided our studies on the intracellular mechanisms of estrogen and ER action in both 
reproductive and non-reproductive tissues. However these systems do not allow to 
get an insight on the exact physiological functions of these receptors. The availability 
of mice in which ERα (ERKO), ERβ (BERKO) or both receptors have been 
inactivated (DERKO) provided the opportunity, for the first time, to gain an insight 
of the potential functions of these receptors in reproductive and non-reproductive 
organs (Couse and Korach, 1999; Dupont et al., 2000).These studies proved that 
malfunctioning of ERs is associated to major deficits of the skeletal, cardiovascular, 
nervous and immune systems. However, in these systems the understanding of ER 
functions is revealed by mutant phenotypes which often are the resultant of several 
adaptive changes. Furthermore, these systems do not allow to examine the 
physiological relevance of ER activity at selected period of life, like for instance at 
menopause. Reporter animals provide us the opportunity to overcome these 
shortcomings because enable to visualize in real time the state of ER activity in 
specific organs (Maggi and Ciana, 2005). Knowing when and where the ER is in the 
transcriptionally activated state directs the study toward a subsequent evaluation of 
the mechanism and of the direct consequences of ER activation (e.g. characterization 
of regulated genes) which will then allow to gain the desired insight on ER function. 
We have recently generated a reporter mouse, ERE-Luc, by integrating into the 
genome of C57BL/6 mice a transgene in which a luciferase gene is driven by a 
promoter containing a multimerized ERE and a minimal TK promoter (Ciana et al., 
2001). The ubiquitous expression of the transgene is ensured by the presence of 
MAR insulator sequences bordering the transgene (Sturchler-Pierrat et al., 1997). 
This mouse model was generated to expressly report on the state of ER 
transcriptional activity on ERE genes and therefore does not provide any information 
of the activities of ER on other intracellular signalling molecule. This models system 
has revealed of great utility to visualize ER state of activation particularly in cycling 
female mice where it was possible for the first time to determine that the mechanism 
of ER activation differs in reproductive and non-reproductive organs (Ciana et al., 
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2003). These findings open several questions on the actual state of activity of ERs 
after cessation of ovarian functions in non-reproductive organs. 
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AIM OF THE THESIS 
The aim of my studies was to evaluate the effect of aging and blockade of ovarian 
functions on estrogen receptor transcriptional activity and ER anti-inflammatory 
action . 
In specific aim #1 we proposed to study genes driven by ERE-containing promoters: 
endogenous as well as surrogate reporters; within specific aim #2 we proposed to 
provide support to the theory that lack of estrogen anti-inflammatory activity is a 
major component for the onset of pathologies associated with menopause 
(osteoporosis, atherosclerosis, metabolic and neurological dysfunctions). 
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Results 
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ER ACTIVITY DURING THE MENOPAUSE 
TRANSITION AND IN AGING. 
We still do not know the extent to which ER activity is affected by menopause. It is 
conceivable that the lack of circulating estradiol induces up-regulation of the ERs, 
and, as a consequence, the minimal quantities of estrogens produced by organs other 
than the ovaries (kidney or fat) might be sufficient to maintain the activity of 
estrogen receptors. On the other hand, previous studies in young, cycling female 
mice showed that in non-reproductive organs the transcriptional activity of ERs is 
regulated by factors other than 17β-estradiol (E2) (Ciana et al., 2003). The knowledge 
of the exact state of ER transcriptional activity during the menopause transition and 
in aging is of primary relevance to the design of future therapies aimed at re-
establishing the exact mechanisms responsible for ER activity in non-reproductive 
organs. 
a) Experimental groups:  
to study the effect of aging and the relevance of ovarian function in thus process we 
carried out studies in intact (sham operated) and ovx (at 5 month) mice. ER activity 
was evaluated at month 6, 12, 18 and 22. 
b) Experimental protocol:  
to overcome any dietary influence in our studies on ER state of activity, we 
generated a completely synthetic diet which did not activate ERs in the ERE-Luc 
mice. These results led us to establish a protocol to be followed to study ER activity 
in ERE-Luc mice. Mice are maintained with regular chow and then shifted to the 
synthetic food 48 hours before the experiment. This time is sufficient to eliminate all 
estrogenic compounds present in the food. To evaluated ER transcriptional activity in 
aging and after ovx we first studied the expression of the reporter luciferase (by 
measuring luciferase mRNA and luciferase enzymatic activity ex vivo and in vivo. 
Next we evaluated the expression of ER endogenous genes such as Prothymosin 
alpha (PTMA) (Martini et al., 2000) and Progesteron Receptor (PgR) known to be a 
direct target of ER. To verify that ER synthesis was not modulated by aging, we 
investigated ER mRNA content in the tissues selected for our studies: i.e. aorta, liver 
and in a brain region.  
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1. AGING EFFECT ON ERα EXPRESSION IN SPECIFIC 
TISSUES. 
The study of the changes of ERα expression during female aging demonstrated that 
aging does not cause a generalized decreased of receptor synthesis, indeed Fig.1 
shows a significant increase of ERα content in aorta and uterus at 22 months of age, 
in liver ER is decreased while no significant change was observed in hippocampus. 
These data suggest that ER expression with age changes in function of the tissue 
taken in consideration but not in relation to the specific role plaied by the organ 
itself. 
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Figure 1 Aging does not affect negatively ER synthesis . 
RT-PCR detection of ER alpha RNA levels in aorta, uterus, liver and hippocampus. Groups 
of six female animals were operated at 5 months of age (sham operated mice) and at due 
time (6, 12, 18 and 22 months) were euthanized for RT-PCR analysis on extract tissues. The 
data are expressed as relative expression and calculated by 2-∆∆Ct method (Livak et al., 2001). 
*p<0.05 versus group at 22 months of age as calculated by one-way ANOVA followed by 
Bonferroni post-hoc test. 
 
2. ER ACTIVITY CHANGES WITH AGING  
a) Study of ER activity on the surrogate target ERE-Luc. 
First, we evaluated ER activity by measuring luciferase mRNA and activity in mice 
of different ages. As shown in Fig.2 (A, B), Luciferase mRNA content in aorta, liver 
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and uterus did not change significantly in relation to age, while the activity of the 
protein decreased in strict association with age. 
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Figure 2 Evaluation of ER activity by study the expression and the activity of 
Luciferase. At month 6, 12, 18 and 22, six sham mice were sacrificed to collect different 
tissues. (A) RT-PCR analysis of Luciferase content, the data are expressed as relative 
expression, the aging does not influence Luciferase mRNA. (B) Luciferase enzymatic assay, 
the luminescence data, normalized over protein content of each sample are expressed as 
relative light units for µg of protein. The activity of protein decreases with aging in liver, 
*p<0.05 versus groups at 18 and 22 months of age as calculated by one-way ANOVA 
followed by Bonferroni post-hoc test. 
 
b) Study of ER activity on endogenous target genes. 
Next, we measured the mRNA of the well known targets of E2-ER the proliferation 
marker PTMA and PgR (Fig.3) unfortunately this receptor is not expressed in the 
liver and therefore the analysis was carried out only in three of the tissues selected.  
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Figure3. Evaluation of ER activity by study the expression of endogenous target genes. 
(A) Real time PCR of PTMA on aorta, uterus, liver and hippocampus, (B) Real time PCR of 
PgR on aorta, uterus and hippocampus. Data are expressed as relative expression, *P<0.05, 
**P<0.01 versus mice at 18 and 22 months of age. 
 
PTMA has been shown to serve biological function, this gene may have a dual role 
both intracellulary and extracellulary. Intracellulary PTMA acts both in cytoplasm 
and in nucleus, in this site PTMA affects the activity of several gene transcription; it 
A B
 57 
 
plays an important role in transcription regulation and promotes transcriptional 
activity of the estrogen receptor by sequestering a repressor of ER from the ER 
complex. It has been proposed that expression of PgR determination indicates a 
responsive estrogen receptor (ER) pathway. 
The analysis of the profile of PTMA and PgR mRNA accumulation in aging tissues 
was unexpectedly quite diverse and with the exception of uterus where we observed 
an increased expression of both PTMA and PgR with aging. However this change 
had not been observed when luciferase activity was measured. In the aorta PTMA 
expression increased with age, but no increase in PgR and luciferase was observed. 
Similarly PgR and Luciferase was observed were not affected by aging, while PTMA 
not increased at 18 month of age. In liver PTMA showed a tendency to decrease 
similarly to what observed with luciferase. 
The increased ER activity in the uterus of 18 month old female mice was further 
substained by the study of uterus weight which was clearly influenced by age and at 
18 month which was increased by 95% with respect to 6 months old mice (Fig.4). 
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Figure 4. Uterus weight increases during aging. At due time uterus weight of sham mice 
was evaluated with an analytical balance. Data are expressed as mg of uterus, *P<0.01 
versus animals at 6 months. 
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EFFECT OF LONG TERM OVARIECTOMY ON ER 
ACTIVITY 
In several of the tissues analyzed, ovx had a significant effect on ERα expression, 
particularly in mice 12 and 18 month old which had been ovx at 5 month of age 
(Fig.5). A significant increase of ER expression was found in particular in aorta, 
uterus and hippocampus. In liver there was a trend to increase at 12 months which 
did not result significant. 
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Figure 5. Ovariectomy influences expression of ERalpha in aging ERE-Luc female 
mice. The 5 month old mice were ovariectomyzed and then at 6, 12, 18 and 22 months were 
euthanized to collect the tissues. The mRNA levels of ERα change with ovx and the trend is 
different in reproductive and non reproductive tissues in mice at various ages. *P <0.05, 
**P<0.01, ***P<0.001 sham versus ovx as calculated by two-way ANOVA followed by 
Bonferroni post-hoc test. 
 
sham 
ovx 
 59 
 
a) Study of ER activity on the surrogate target ERE-Luc after ovariectomy. 
The increased synthesis of ER alpha did not appear to influence significantly ER 
activity on the surrogate reporter luciferase considering both mRNA (Fig. 6A) 
and enzymatic activity (Fig. 6B) . Even if a trend to increase was observed in 
aorta and uterus at 18 month of age. 
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Figure 6. Evaluation of ER activity by study the expression and the activity of 
Luciferase. in aging ovx mice. (A) RT-PCR analysis of Luciferase content, the data are 
expressed as relative expression, the ovariectomy does not influence negatively Luciferase 
mRNA. (B) Luciferase enzymatic assay, the luminescence data, normalized over protein 
content of each sample are expressed as relative light units for µg of protein. The activity of 
protein increases with aging in uterus and in liver after ovaries failure. 
 
b) Study of ER activity on endogenous target genes in aging ovx mice . 
Conversely, when we studied the expression of endogenous target genes we observed  
the effect of the increased synthesis of ER alpha on the target tissues taken in 
consideration. PTMA mRNA content changed with ovariectomy in aorta, uterus and 
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hippocampus; in liver we observed a similar trend between sham and ovx of PTMA 
mRNA. PgR content increased significantly only in uterus. In aorta at 12 months and 
the expression of receptor in ovx group was higher than sham group; in hippocampus 
ovx and sham PgR levels did not change(Fig. 7). 
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Figure 7. Evaluation of ER activity by study the expression of endogenous target genes 
in aging ovx mice. (A) Real time PCR of PTMA on aorta, uterus, liver and hippocampus in 
mice after ovariectomy (at 5 month), (B) Real time PCR of PgR on aorta, uterus and 
hippocampus during menopause. Data are expressed as relative expression, *P<0.05, 
***P<0.01 sham versus ovx as calculated by two-way ANOVA followed by Bonferroni 
post-hoc test. 
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COMPARATIVE ANALYSIS OF ER ACTIVITY IN 
AGING FEMALE AND MALE MICE. 
Several disorders are characterized by the gender difference . The different phases in 
the reproductive life or female hormonal instability seem to play a role in the gender 
difference. From these observations, we decided to compare the state of ER 
transcriptional activity after gonadectomy in aging female and male mice. 
a) Experimental groups:  
to study the effect of aging and the relevance of gonadal function in gender 
difference we carried out studies in intact (sham operated) and ovx/orx ( at 5 month) 
mice. The pattern ER activity was evaluated at month 6 and 20. 
b) Experimental protocol:  
To evaluated ER transcriptional activity in aging and after gonadectomy we treated 
mice with luciferine and after 20 minutes the whole body photon emission was 
analysed and luciferase activity was quantificated as counts per unit of time and area 
[cts/(cm2s)]. Then we compared data obtained in different animals or in the same 
animal at different time points with a template mask enabling to evaluate, 
reproducibly, photon emission from selected body areas: head, limbs, tail, chest, 
abdomen and thymus. 
In young female mice after ovariectomy, ER activity decreased significantly in bone 
(head, limb and tali), in genital and in chest; in young male gonadectomised this 
activity decreased only in chest and abdomen (Fig,8; Fig.9). At 20 months of age we 
observed a sexual dimorphism:in the ER activity; interestingly in ovariectomized 
females the activity was increased significantly in breast, chest and abdomen while in 
gonadectomized males the activity of receptor was decreased in all areas. (Fig.10, 
Fig.11). In aged gonadectomized male mice may decreases the concentration of other 
factors that activate the receptor, while in aged female mice the ovariectomy may 
activate a pathway of ER activation regulated by factors other than 17β-estradiol. 
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Figure 8. Ovariectomy decreases luciferase expression in selected organs of female mice 
at 6 months of age. ERE-Luc female mice were bilaterally ovariectomized (n=6) and 
luciferase pattern was obtained by bioluminescence in sham operated and in ovx. Data are 
expressed as photon emission *P<0.05, ***P<0.01 sham versus ovx as calculated by t Test.  
 
 
Figure 9. Orchidectomy reduces ER activity in male ERE-Luc mice at 6 months of age.  
Male mice were bilaterally orchiedectomized (n=6) and luciferase pattern was obtained by 
bioluminescence in sham and orx. Data are expressed as photon emission *P<0.001 sham 
versus orx as calculated by t Test. 
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Figure 10. Ovariectomy increases ER activity in female mice at 20 months of age. ERE-
Luc female mice were bilaterally ovariectomized (n=6) from 14 months and luciferase 
pattern was obtained by bioluminescence in both groups. Data are expressed as photon 
emission *P<0.05, ***P<0.01 sham versus ovx as calculated by t Test. 
 
 
Figure 11. Orchidectomy affectes negatively ER activity in in aging male ERE-Luc 
mice. Male mice were bilaterally orchiedectomized (n=6) at 5 months of age and luciferase 
pattern was obtained by bioluminescence in sham and orx. Data are expressed as photon 
emission *p<0.05 sham versus orx as calculated by t Test. 
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INFLAMMATION AND AGING 
Inflammation is a common component of all pathologies associated with menopause 
(osteoporosis, arteriosclerosis, diabetes, dementias). The inflammatory state triggers 
biochemical alterations and leads to tissue degeneration. Quenching the chronic 
production of inflammatory mediators and limiting the damage induced by free 
radicals and toxic agents is expected to slow down the progression of most aging 
diseases. Estrogens were shown to play a strong anti-inflammatory activity in in vitro 
and in vivo model systems: Several years ago we observed that ER is expressed in 
macrophages, in smooth muscle cells in culture estrogens may inhibit the synthesis 
of iNOS induced by selected inflammatory stimuli. This led us to further investigate 
the potential anti-inflammatory action of estrogens using a model of carageenan 
induced pleurisy, estrogen deprivation-dependent osteoporosis and microglia 
inflammation in response to lipopolysaccharide (LPS) treatment (Vegeto et al., 2003; 
Vegeto et al., 2006; Vegeto et al., 2002). In all of these studies estradiol appeared to 
exert an anti-inflammatory activity via ERα, but not ERβ, and the anti-inflammatory 
effect was observed only when E2 was administered before the inflammatory stimuli. 
Next we investigated on the molecular mechanism of estrogen-ERα anti-
inflammatory action and showed that E2 prevents NF-kB transcriptional activity by 
inhibiting its transport to the nuclear compartment in inflammatory cells. This 
activity was mediated by ERα through a non-genomic, phosphatidylinositol-3-OH 
kinase-dependent pathway that does not modify Ik-Bα degradation, thus indicating a 
novel mechanism for estrogen action that is not shared by other anti-inflammatory 
drugs. The peculiarity of this mechanism may suggest that estrogens exert an unique 
function in inflammation. 
Yet, it is still unknown to which extent a prolonged reduction of the levels of 
circulating estradiol influences the state of inflammation in the different organs.  
Due to the considerable length of time required before the manifestation of the 
symptoms of an inflammatory disorders associated to menopause, it is still unclear 
when the inflammatory process starts to be established. We therefore proposed a 
study aimed at understanding the extent to which menopausal transition is associated 
with an increased basal inflammatory status of the different tissues. 
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a) Experimental groups:  
to have a direct assessment of the effects induced by short and long term lack of sex 
hormones in basal inflammatory process, groups of animals were been 
ovariectomized at 5 months of age and inflammatory signs evaluated at 6, 12,18 and 22 
months of age in specific tissues.  
b) Experimental protocol:  
to evaluate a basal inflammatory status associated with aging and menopause we first 
studied the expression of four inflammatory markers: TNFα and IL1β which are 
known to be involved in the acute inflammatory response and MCP1 and MIP2 
which are involved respectively in the recruitment of macrophages and neutrophils in 
the chronic inflammatory response.  
It s well known that the brain is one of the organs where inflammation, driven by 
brain microglia and by astrocytes, plays a relevant role after menopause, thus we 
evaluated the expression of microglia and by astrocytes in different brain areas. 
Using a cryostat, we collected brain sections from different levels of the brain which 
we analysed by immunohistochemistry using antibodies directed against activated 
microglia (i.e., Mac-1 for complement 3 receptor), and GFAP, a marker for 
astrocytes. 
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1. AGING EFFECT ON INFLAMMATORY MARKERS 
EXPRESSION IN SPECIFIC TISSUES  
The expression of all markers of inflammation increased significantly at 22 months 
of age (Fig.12, 13, 14). 
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Figure 12. Aging increases TNFα synthesis. 
RT-PCR detection of TNF alpha RNA levels in aorta, uterus, liver and hippocampus. Groups 
of six female animals were operated at 5 months of age (sham operated mice) and at due 
time (6, 12, 18 and 22 months) were euthanized for RT-PCR analysis on extract tissues. The 
data are expressed as relative expression and calculated by 2-∆∆Ct method (Livak et al., 2001). 
*P<0.05 versus group at 22 months of age as calculated by one-way ANOVA followed by 
Bonferroni post-hoc test. 
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Figure 13. Aging affects Il1 beta synthesis. 
The expression of Il1 beta was measured by semiquantitative real-time PCR assay on total 
mRNA extracted from aorta, liver and hippocampus. Bars represent the mean ± SEM of at 
least six mice. *P<0.05; **P<0.01,***P<0.001 versus 22m sham. P values were calculated 
with ANOVA followed by Bonferroni’s test. 
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MCP1 mRNA
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Figure 14. Aging increases MCP1 mRNA content. 
The expression of chemokine was quantified by real-time RT-PCR and was significantly 
increased by age in aorta and liver. Graphs represent mean ± SEM. *P < 0.05; **, **P < 
0.01; ***, P < 0.001 young versus aged mice. 
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Figure 15. Aging increases MIP2 synthesis. 
mRNA accumulation of the mip2 gene was measured by real-time PCR in aorta, uterus, liver 
and hippocampus of aged mice. Bars represent the mean ± SEM of 6 mice. *P<0.05 versus 
group at 22 months of age as calculated by one-way ANOVA followed by Bonferroni post-
hoc test. 
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2. EFFECT OF ESTROGEN DEPRIVATION ON 
INFLAMMATION 
In ovariectomized female mice there was not a clear factor of modulation, at 22 
months the trend was that ovariectomy reduced inflammation while in uterus but 
mainly in hippocampus the expression of citokines and chemokines increased 
(Fig.16). 
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Figure 16. Ovariectomy affects TNFα synthesis. 
RT-PCR detection of TNF alpha RNA levels in aorta, uterus, liver and hippocampus. Groups 
of six female animals were ovariectomized at 5 months of age and at due time (6, 12, 18 and 
22 months) were euthanized for RT-PCR analysis on extract tissues. In aorta and liver ovx 
reduced the gene expression at month 22 while in uterus and hippocampus the trend is 
opposite. The dotted bars represented a ovx grup and*P < 0.05; **, **P < 0.01; ***, P < 
0.001 sham versus ovx. P values were calculated with two way ANOVA followed by 
Bonferroni post-hoc test. 
Il1 beta mRNA
6 12 18 22
0
2
4
6
8
6 12 18 22
0
2
4
6 **
6 12 18 22
0
1
2
3
4
5
R
el
at
iv
e 
E
xp
re
ss
io
n 
(2
-Δ
Δ C
t )
R
el
at
iv
e 
E
xp
re
ss
io
n 
(2
-Δ
Δ C
t )
R
el
at
iv
e 
E
xp
re
ss
io
n 
(2
-Δ
Δ C
t )
months months months
Aorta Liver Hippocampus
Figure 17. Estrogen deprivation acts on IL1 beta mRNA content. 
The expression of Il1 beta was measured by semiquantitative real-time PCR assay on total 
mRNA extracted from aorta, liver and hyppocampus in ovx mice. Bars represent the mean ± 
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SEM of at least six mice. **P<0.01 sham versus ovx. P values were calculated with two 
wayANOVA followed by Bonferroni’s test. 
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Figure 18. Ovariectomy does not affected the synthesis of MCP1 mRNA content. 
mRNA accumulation of the mcp1 gene was measured by real-time PCR in aorta, liver and 
hippocampus of sham and ovx mice. 
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Figure 18. Estrogen deprivation has a different effect on MIP2 expression. 
mRNA content was evaluated by real-time RT-PCR and was significantly increased by 
ovariectomy at 6, 12, 18 months respectively in aorta, uterus and liver. *P < 0.05; **, **P < 
0.01; ***, P < 0.001sham versus ovx. P values were calculated with two way ANOVA 
followed by Bonferroni post-hoc test. 
 
3. EFFECT OF AGING AND ESTROGEN DEPRIVATION ON 
MICROGLIAL CELLS AND ASTROCYTES.  
We performed an immunoistochemical study of different brain areas: frontal cortex, 
straitum, hypothalamus and hyppocampus, in sham and ovariectomized ERE-Luc 
mice from 6 to 22 months of age. In hippocampus there were morphological 
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differences among astocytes between ovariectomized and sham operated mice, 
indeed in ovx animals astrocytes seem with thick filaments, typical filaments of 
reactive astrocytes associated a state of inflammation. Also microglial cells were 
more reactive in ovariectomy group, but  either reactive cells growth in number in 
group of sham while in ovx animals the number was similar in all time points 
(Fig.20). 
 
          
 
 
       ..  
 
 
Figure 19. Aging and estrogen deprivation affects number and morphological aspect of 
astrocytes and microglial cells in frontal cortex and striatum. Immunohistochemical 
assay was performed in brain areas of aging female ERE-Luc mice sham and ovx with 
GFAP and MAC-1 markers. Astrocytes were morphological different between two group at 
all time points (top panel). The number of microglia cells was higher in ovx than sham at 
6,12,18 and 22 months (bottom panel). 
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Figure 20. Aging and ovariectomy affects number and morphological aspect of 
astrocytes and microglial cells in hypothalamus and hippocampus. 
Immunohistochemical assay was performed in brain areas of aging female ERE-Luc mice 
sham and ovx with GFAP and MAC-1 markers. Number of astrocytes were increased in 
sham from 6 to 22 months of age; in ovx these cells were morphological different with aging 
(top panel). Microglia cells were reactive both in sham and ovx group (bottom panel). 
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ROLE OF BRAIN INFLAMMATORY STIMULI ON 
INFLAMMATORY GENE EXPRESSION DURING AGING AND 
IN MENOPAUSE 
Several studies revealed a higher number of reactive microglia cells in the brain of 
female as compared with male mice and that ovariectomy increases microglia 
activation. In addition, we observed that the brain of ERα-knock out mice show an 
increased expression of complement-3 receptor by microglia cells as compared to 
age-matched wild-type littermates, suggesting that the lack of the endogenous 
mediator of estrogen anti-inflammatory activity results in a partial reactivity of brain 
macrophages. Because of our expertise, we selected the brain as a paradigmatic 
organ in which to study the decreased defence to inflammatory stimuli due decreased 
circulating estradiol.  
The acute response of the brain following inflammatory stimuli is supposed to 
eliminate the toxic insult together with restraining cell damage and restoring tissue 
integrity. However, it is not known whether this response is similarly maintained or 
is somehow impaired in the aging brain. Thus we decided to evaluate the acute 
response of the brain to inflammatory agents in mice of different ages and hormonal 
statuses. 
a) Experimental groups:  
To evaluate the inflammatory response following an inflammatory stimulus in the 
brain in mice during aging, we induced brain inflammation by 
intracerebroventricular (icv) injection of lypopolisaccharide (LPS: a potent 
inflammatory agent) or saline in female intact and ovariectomized (at month 2 or 5) 
ERE-Luc mice at different ages.  
b) Experimental protocol:  
After three hours to icv, hippocampus were collected for real time PCR experiments 
on inflammatory cytokines and chemokines: TNFα, Il1b, MCP1 and MIP2 
Our results in the hippocampus showed that the levels of the four cytokines are: 
TNFα production did not increase with ovariectomy at 18 months of age, 
IL1β production didnot increase with estrogen deprivation, 
MCP1 production increased with ovariectomy at 12 and 18 months of age,  
MIP2 production increased only at 12 months of age with estrogen deprivation. 
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Furthermore, all inflammatory analyzed markers with a short term ovariectomy 
(performed at 11 months of age), decreased with aging (Fig. 21). 
 
 
Fig. 21 Effect of  long and short term ovariectomy on Expression of TNFα, Il1beta, 
MCP1 and MIP2 in aging ERE-Luc female mice in hippocampus after inflammatory 
stimuli. The mice are treated with LPS after three hours to injection, hippocampus was 
removed and expression of chemokines and cytokines was valuated by RT-PCR. 
*P < 0.05 sham versus ovx and ovx-1; *P < 0.05 ovx versus ovx-1; P values were calculated 
with two way ANOVA followed by Bonferroni post-hoc test. 
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Discussion 
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In our study we evaluated ER activity during aging in ERE-Luc mice. The study 
shows that in aged mice ERα is still synthesized at the rate observed in young and 
adult mice (hippocampus) or at higher rate (uterus and aorta). In the liver we 
measured a decrease of ERα content with time: at 22 months of age the amount of 
hepatic estrogen receptor is about 50% lower than at month 6. With age, ovariectomy 
further increases ERα content in uterus, aorta and hippocampus, but not in the brain.  
The study of luciferase, as well as the two ER gene targets: prothymosine (PTMA) 
and Progesterone Receptor (PgR), showed that the ER present in aged tissues is fully 
functional from the transcriptional point of view, indeed in hippocampus, aorta and 
uterus of mice at 18 and 22 month of age PTMA mRNA content is higher than in 
young mice, PgR mRNA increases with age (22m) only in the uterus. The fact that, 
in some tissues, luciferase accumulates at the different rate than endogenous genes 
target for the ER has to ascribe to the different complexity of the promoters 
regulating the Pol II activity: in the ERE-Luc mice the construct carrying the 
luciferase reporter was conceived to be a very precise indicator of the state of ER 
transcriptional activity, thus to highlight ER action in the absence of other factors 
(thus the construct is composed of a very simple promoter with a multimerized ERE 
and a minimal TK driving the luciferase). On the other hand, each natural, 
endogenous gene is under the control of very complex promoters, where the final 
transcriptional activity is determined by a number of regulators which activity may 
change significantly spatiotemporally.  
The increased content of PTMA mRNA in the uterus of mice at 18 months of age is 
in line with the uterus weight previously reporter and attributed to a hyperactivation 
of the production of estrogen by the ovaries (Sherman et al., 2007). However PTMA 
mRNA content is also increased significantly by ovariectomy, which leads to a 
decrease of uterus weight. We hypothesize that the increase PTMA mRNA after ovx 
may be due to inflammatory processes occurring in this organ and leading to 
proliferation of inflammatory cells.  
We were intrigued by the observation that, in aged female mice, a reduction of 
circulating levels of estrogens induced by ovariectomy was associated with an 
increased ER activity in several organs. To further study this phenomenon, we 
gonadectomised male and female mice at the age of 5 months and we measured 
luciferase activity by in vivo imaging at 6 or 20 months of age. As expected 
 76 
 
luciferase activity was higher in females than in males in both groups of age, 
however a few observations were unexpected: 
1. aging was associated with a decrease of photon emission in females, but not in 
males; 
2. in young female animals ovariectomy reduced significantly luciferase content in 
several organs (bone, genital area and liver); however this was not the case in aged 
mice, where ovariectomy was mainly associated with an increase of luciferase 
activity; 
3. gonadectomy did not affect luciferase activity in young males (with the exception 
of the chest), but clearly decreased photon emission in aged mice. 
Clearly, in young females, the ovaries are the main source of endogenous ligands for 
the estrogen receptor and it was expected that gonadectomy would have induced a 
general decrease of luciferase synthesis; in males, the enzyme converting 
testosterone into estrogens is present in several organs and therefore was not 
surprising to observe that the surgical removal of the gonads did not affect luciferase 
activity. More puzzling were the results in aged animals, where ER activity was 
slightly decreased in the females. However ovariectomy was not associated with 
decreased luciferase activity, indicating that, with age, sources other than the gonads 
are generating signals able to activate the estrogen receptor transcriptionally. The 
opposite was true for the aged males where gonadectomy decreased ER activity in 
most of the organs studied, suggesting that in males the aging process leads the 
gonads to become the only source of estrogens. 
Taken togheter, these data indicate a different regulation of estrogen receptor in both 
sexes and particularly the existence of different factors that are active on ER in aged 
females.  
On these bases our data support the possibility of an activation of the estrogen 
receptor independent from plasmatic estrogens, that during aging are partially 
replaced by other factors active on ERs (i.e., IGF1 and other growth factors).  
In our study we also tested the hypothesis that with aging the loss of the anti-
inflammatory activity of estrogens may explain the increased susceptibility to 
inflammatory disorders (i.e., osteoporosis, atherosclerosis, diabetes, certain 
neurodegenerative disorders), reported by epidemiological studies in women.  
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Our results, on the expression of inflammatory genes in selected tissues, agree 
previous preclinical and epidemiological studies that indicate that the aging process 
is connected with a significant increase in pro-inflammatory factors. Our study 
focused primarily on TNFα, IL1 beta, MCP1 and MIP2. The mRNA of all these 
inflammatory mediators was shown to increase progressively with aging. 
To evaluate the influence of estrogens on the expression of inflammatory genes, we 
measured the content of mRNA encoding for inflammatory mediators in different 
tissues of ovariectomized females. Most interestingly, we observed that in 
ovariectomized mice the activity of the inflammatory genes, increased with aging in 
uterus and hippocampus, while decreased in aorta and liver. Due to the relevance of 
inflammatory processes in the CNS, we next focused on the effect of ovariectomy in 
the hippocampus by IHC studies the state of reactivity of microglia and astrocytes, 
cells known to play a relevant role in neuroinflammation. Our data show 
morphological differences between astrocytes in the hippocampus and striatum in 
ovariectomized compared to sham operated mice already at the age of 6 months: 
astrocytes in ovx group are reactive with tick processes. At 12 months of age 
astrocytes are activated and proliferating in the hypothalamus of ovariectomized 
animals; at 18 and 22 months the differences in morphology and number of 
astrocytes affect all the brain areas. Also microglia presents a morphological 
activation in all the brain areas, as observed in astrocytes. 
Finally we investigated the extent to which the susceptibility to an inflammatory 
stimulus changed during aging and if the ovariectomy was playing a role in this 
phenomenon. In the hippocampus TNFα production increases with aging, MIP2 and 
MCP1 espression changes at 12 months and is similar at 18 months, whereas mRNA 
levels of IL1 beta are not affected by aging.  
Ovariectomy does not seem to influence the inflammatory process indeed: 
1. TNFalpha production does not increase with OVX at 18 months of age;  
2. IL1 beta production does not increase with OVX;  
3. MCP1 production increases with OVX at 12 and 18 months of age; 
4. MIP2 production increases with OVX only at 12 months of age. 
The present study, for the first time, provides a systematic analysis on the activity of 
estrogen receptor in females during aging in reproductive and non-reproductive 
organs. The main merit of the study is to have demonstrated that ER is still expressed 
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in aged tissues and its activity may be stimulated to an extent similar to what 
observed in young tissues:  the finding that ER is still synthesized and active in aged 
mammals could provide an explanation for the negative effects observed in the 
women of the NIH Women Health Study (Women’s Health Initiative Memory 
Study). Infact, several cardiovascular effects were observed in the very first year of 
the study, particularly in women who had undergone menopause several years before 
the beginning of the investigation. Indeed, it could be hypothesized that the 
administration of a full dose of therapeutic hormone might have triggered an 
abnormal response, leading to the pathological outcome reported.  
The data so far obtained on the effect of ovariectomy on inflammation need further 
analysis and study: apparently ovariectomy in aged mice does not clearly increase 
the susceptibility to inflammatory stimuli. However, the study also shows that in 
aged mice signals other than estrogens have the ability to modulate ER activity: it 
would be most relevant to identify the molecular nature of these stimuli in order to 
achieve a better understanding on their exact physiological significance and 
relevance to ER activity in both reproductive and not reproductive tissues.  
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Materials and methods 
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Chemical used 
Ketamine (Imalgene 500) from Merial (Tolouse France), and xilazine (Rompun) 
from Bayer (Shawnee Mission, Kansas, USA), D-luciferin (Beetle luciferin 
potassium salt) from Promega (Milan, Italy), Escherichia coli LPS (serotype 
0.111:B4 from Sigma (Milan, Italy). 
 
ERE-Luc reporter mouse system 
The ERE-Luc mice were generated to obtain the ubitous expression of an estrogen-
regulated reporter gene. In the following image (Fig.1) we describe the structure of 
the trangene used for the generation of the reporter mouse: 
 
 
a) the trangene is flanked by two insulators sequences (MAR sequence) that 
create open chromatin domains permissive to gene expression. They 
constitute a barrier against acetylation and methylation events, thus 
preventing the position effects and ensuring an ubiquitous expression of the 
trangene; 
b) the estrogen-inducible promoter is generated using deleted mutants of the 
minimal promoter from the thymidine kinase (tk) gene from Herpes simplex 
virus linked to a combination of two palinfromic receptor-responsive 
elements (EREs). The two EREs are spaced 8bp and located 55bp from the tk 
promoter; this structure provides the desired low basal trascription and an 
high estrogen-induced reporter expression; 
c) the reporter gene sequence  
The activation of estrogen-receptors through specific binding ligands leads to the 
translocation of the receptor complex into the nucleus where it interacts with several 
co-factors and binds the estrogen responsive elements of the promoter. In this case 
luciferase is produced and can be detected by different assays such as 
5’-MAR 3’-MAR
ERE 2x
TK
LUCIFERASI
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immunohistochemistry, that allows tissue and cellular localization of the ERE 
activation, quantitative enzymatic assays on tissue extract or optical imaging 
technology. This last methodology is the most used in our lab because, by the use of 
a charge-coupled device (CCD), it allows an easy and real-time visualization of the 
bioluminescence produced by luciferase expression in living animals. 
After an injection of luciferine the whole body photon emission can be analysed and 
luciferase activity can be quantificated as counts per unit of time and area 
[cts/(cm2s)].To be able to compare data obtained in different animals or in the same 
animal at different time points we generated a template mask (Fig.2) enabling to 
evaluate, reproducibly, photon emission from selected body areas. 
 
                 
Fig. 2 Template enabling the evaluation of bioluminescence in the following areas: head, 
thymus, liver, intestine, gonads, limbs and tail. 
 
Ovariectomy 
Weigh and anesthetize animal with doses of anesthetics recommended in standard 
procedures. Confirm that the animal shows a reduced respiratory rate and no 
response to gentle pinching of foot pad. Shave both flanks of the animal. In the 
mouse, shaving is optional. Swab the shaved area with 70% ethanol. All instruments 
should be sterilized by dipping in 90% ethanol and then flaming in a Bunsen Burner 
or by other accepted methods of sterilization.  
A 5mm, dorsal/ventral incision is made through the skin of the flank of the mouse 
below the muscles surrounding the spinal cord. The incision is centered between the 
bottom of the rib cage and the front of the hind limb. In the rat, a 10mm incision is 
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placed in a similar fashion. The skin is separated from the underlying muscle. Before 
making the incision through the muscle overlying the ovary, confirm the location of 
the ovarian fat pad which is sometimes visible under the muscle. Rather than cutting 
the muscle, insert the tip of double sharp iridectomy scissors just through the muscle 
layer, and separate the muscle fibers by opening the scissors in a dorsal ventral 
direction. Hold the edge of the incision open with a small rat tooth forceps and pull 
the ovary through the incision with a blunt forceps by grasping the fat pad 
surrounding it. Place a mosquito hemostat at the boundary between the oviduct and 
uterus, and place a ligature just below the hemostat. After removing the ovary and 
oviduct with a scissors, release the hemostat and make sure no bleeding occurs. 
Return the ovary to the abdominal cavity, and suture the muscle layer if necessary. 
Close the skin incision with wound clips. Turn the animal over and repeat the 
procedure on the other side. Return the animal to its cage and leave undisturbed in a 
warm, quiet place. Monitor the animal continually until it is completely recovered 
from anesthesia. If clear signs of pain, acute discomfort, or adverse reaction to the 
drug are apparent (e.g., convulsions, respiratory distress), the animal should be 
euthanized. Following recovery, the animal should be monitored daily for one week 
for signs of infection or persistent problems, in which case the animal should be 
euthanized.  
 
Orchidectomy 
Weigh and anesthetize animal with doses of anesthetics recommended in standard 
procedures. Confirm that the animal shows a reduced respiratory rate and no 
response to gentle pinching of food pad. Shave the abdominal region of the animal. 
Swab the shaved area with 70% ethanol. All instruments should be sterilized by 
dipping in 90% ethanol and then flaming in a Bunsen burner or by other accepted 
methods of sterilization. Make a 1.5 cm, transverse incision in the skin at a point 
level with the top of the legs. Separate the skin from the muscle layer. See diagram 
provided for the standard procedure for vasectomy. Make a similar incision through 
the abdominal muscle. Both testes can be reached through the same incision. 
Localize the testicular fat pad on the left side and pull it through the incision using a 
blunt forceps. Place a hemostat below the testes and epididymis across the testicular 
cord (contains blood vessels and vas deferens). Place a ligature below the hemostat 
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and remove the testes and epididymis with a scissors. Repeat for right testes. Suture 
the abdominal wall with 2-3 stitches and repeat for skin incision. (Wound clips can 
be used for skin incision, but sutures are recommended because the body clip can 
affect sexual proclivity).Return the animal to its cage and leave undisturbed in a 
warm, quiet place. Monitor the animal continually until it is completely recovered 
from anesthesia. If clear signs of pain, acute discomfort, or adverse reaction to the 
drug are apparent (e.g., convulsions), the animal should be euthanized. Following 
recovery, the animal should be monitored daily for one week for signs of infection or 
persistent problems, in which case the animal should be euthanized. 
 
Experimental animals 
2 and 5 month old heterozygous ERE-Luc reporter mice were housed in plastic cages 
with hardwood chips bedding at Harlan (Bresso, Milan) animal facilities. Mice were 
fed ad libitum with a certified estrogen-free AIN93-M diet (Mucedola, Settimo 
Milanese, Milan, Italy), and had free access to filtered water. The animal room was 
maintained within a temperature range of 22–25°C and relative humidity of 
50%±10%. There was a cycle of 12 hours light/dark (lights on, 07:00 AM). Mice 
were euthanized at the time described in the figure legends and the indicated tissues 
rapidly dissected and stored at -80°C until assayed. All animal experimentation was 
carried out in accordance with European guidelines for animal care and use of 
experimental animals, approved by the Italian Ministry of Research and University, 
and controlled by the panel of experts of the Department of Pharmacological 
Sciences, University of Milan. 
 
Anaesthesia 
Mice were anaesthetized with s.c. injection of 50 μL of a ketamine-xylazine water 
solution (78% ketamine (Ketavet 50 mg/mL, Intervet, Peschiera Borromeo, Italy) 
and 15% xylazine (Rompun 20 mg/mL, Bayer, Leverkusen, Germany) This amount 
corresponded to a dosage of 78 mg/kg (ketamine) and 6 mg/kg (xilazine). 
 
Vaginal smears 
The phase of the estrous cycle was established by vaginal smears using about 20 µL 
of fluid collected by water vaginal flush smeared onto a glass microscope slide. The 
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smear was air-dried and stained with the May Grunwald e Giemsa method (MGG 
Quick Stain Kit, Bio-optica, Milan, Italy) following the manufacturer’s protocol. 
Cytological assessment was done with an AxioCam HRc and an Axioskop 2 mot 
plus (Zeiss, Germany) at the magnification of 100x. The smears were done at 9:00 
a.m. 
 
Bioluminescence Imaging (BLI) 
Briefly, a CCD consists of a sensor for recording images, consisting of an integrated 
circuit containing an array of linked, or coupled, capacitors. Under the control of an 
external circuit, each capacitor can transfer its electric charge to one or other of its 
neighbours enabling to generate a digital image based on optical and UV 
spectroscopy. In principle, the CCD enables also to quantify the photons emitted by 
selected areas of a living animal. 
Under anaesthesia, 20 minutes before BLI, animals were administered i.p. 50 μL of a 
water solution of the luciferase substrate luciferin (Beetle luciferin potassium salt, 
Promega, Madison, WI, USA) corresponding to 50 mg/kg for a 25 g mouse. 
Bioluminescence was measured by a Night Owl imaging unit (Berthold 
Technologies, Bad Wildbad, Germany), consisting of a Peltier cooled charge-
coupled device slow-scan camera equipped with a 25 mm/f 0.95 lens. The camera 
was operated by WinLight32 software (Berthold Technologies). For photon emission 
measurement, mice were placed in a light-tight chamber, a gray-scale image were 
first taken with dimmed light, then luciferase signal was registered for 5 minutes. 
Merging of the pictures enabled to visualize the body areas where photon emission 
occurred (luciferase signal was transformed in pseudo-colors: blue-lowest, white-
highest signal). For quantification, photon emission was measured in selected body 
areas using WinLight32 (Berthold Technologies) by superimposing a standardized 
electronic grid over the hepatic area and integrating the signals (counts per second, 
cts/s). Normalization was performed using an external source of photons (Glowell, 
Lux Biotechnology, Edinburgh, UK) enabling to measure the instrumental efficiency 
of photon counting. 
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Luciferase enzymatic assay 
For luciferase enzymatic assay, tissues were homogenized in 500 µl of ice-cold lysis 
buffer (100 mM KPO4,1 mM DTT, 4 mM EGTA, 4 mM EDTA, pH 7.8) with a 5 
mm inox bead in a Tissuelyser (Qiagen), undergone one freezing-thawing cycle, and 
were centrifuged for 30 minutes at 4900 x g, 4°C (Rotanta 460R Hettich 
Zentrifugen). Supernatants containing luciferase were collected and protein 
concentrations measured by Bradford assay, following reagent’s manufacturer 
instructions (Pierce Biotech). Luciferase enzymatic activity was assessed by mixing 
20 uL of tissue extracts (diluted 1:15 to prevent matrix interference) with 100 uL of a 
commercial luciferase assay buffer (Promega). Light intensity was measured with a 
luminometer (Glomax, Promega) and expressed as relative light units over 10 sec/µg 
protein (RLU/µg prot). 
 
Immunohistochemistry 
Animals were killed under deep anesthesia. Brains were removed and hemibrain 
postfixed in 4% paraformaldehyde, cryoprotected, snap-frozen in liquid nitrogen, and 
stored at -80° C until analyzed. Using a cryostat (Microm,Walldorf, Germany) 30-
μm thickness sections were collected. The distinction between resting and activated 
microglia and astrocytes was based on morphological analysis; for the ERE-Luc 
mice, the mouse antibody Mac-1 was used to specifically stain microglia cells; the 
mouse antibody GFAP, was used to specifically stain activated astrocytes cells. 
Before the immunological assay, sections were incubated in 0.05 M NH4Cl in PBS 
for 30 min at room temperature to saturate aldehyde residues, washed in PBS, 
incubated for 5 min in 1% H2O2 in PBS at room temperature to inhibit endogenous 
peroxidases, and washed three times with PBS. 
GFAP and Mac-1 staining.  
Sections were incubated with rabbit anti-GFAP antibody (1 : 1000, Dako, 
Carpinteria, CA, USA) or rat anti-mouse MAC-1 antibody (1 : 500, BD PharMingen, 
San Diego, CA, USA) at 4°C overnight. Sections were then incubated with 
biotinylated goat anti- rabbit antibody for GFAP (1 : 1000, Vector, Burlingame, CA,) 
or biotinylated rabbit anti-rat antibody for Mac-1 (1 : 500, Vector, Burlingame, CA, 
USA) for 60 min. Immunoreactivity was visualized using ABC elite (Vector, 
Burlingame, CA, USA), an avidin±biotin±horseradish peroxidise (HRP) complex 
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(Vector Burlingame, CA, USA), with diaminobenzidine (DAB) (Sigma, Milan, Italy) 
as the chromogen. 
 Sections mounted on slides were observed using a Zeiss Axioskop microscope 
(Zeiss, Germany) at magnification x 1000 and analyzed with a colorvideo image 
analysis system linked to the microscope. 
 
Real-Time PCR Gene Expression Analysis.  
Real-Time PCR experiments were done with total aorta, uterus, liver and 
hippocampus RNAs extracted with RNeasy® Mini kit (Qiagen, Hilden, Germany) as 
suggested by the manufacturer’s instructions. For the preparation of cDNA, 1 µg 
RNA was denatured at 75°C for 5 min in the presence of 1.5 µg of random primers 
(Promega) in 15 µl final volume. Deoxynucleotide triphosphate (GE Healthcare) and 
Moloney murine leukemia virus reverse transcriptase (RT) (Promega) were added at 
0.5 mM and 8 U/µl final concentration, respectively, in a final volume of 25 µl. The 
RT reaction was performed at 37°C for 1 h; the enzyme was inactivated at 75°C for 5 
min. Control reactions without addition of the RT enzyme were performed for each 
sample. Real-Time PCR experiments were performed using TaqMan technology. 
The reaction mix for each sample was made up of 5 µl diluted cDNA, 12.5 µl of 
TaqMan 2x Universal PCR Master Mix No AmpErase UNG (Applied Biosystems, 
Foster City, CA) and 7.5 µl of primers and probe mix: 100 nM Luc forward and 
reverse primers (ACA-GAT-GCA-CAT-ATC-GAG-GTG-AA and GCC-AAC-
CGA-ACG-GAC-ATT-T ), 80 nM Luc TaqMan MGB probe 5’-TAC-GCG-GAA-
TAC-TTC; pre-made TaqMan Gene Expression assays for the endogenous gene Esr1 
(Mm00433149_m1, Applied Biosystems), TNFα (Mm00443258_m1, Applied 
Biosystems), IL1β (Mm00434228_m1 Applied Biosystems), Mcp1 
(Mm00441242_m1 Applied Biosystems), Mip2 (Mm00436450_m1 Applied 
Biosystems), PgR (Mm00435625_m1 Applied Biosystems) and as a reference gene 
assay 18S rRNA VIC-MGB-PDAR (Applied Biosystems). The reaction was carried 
out according the manufacturer’s protocol using 7900HT fast real-time PCR system 
(Applied Biosystems) with the following thermal profile: 2 min at 50°C; 10 min at 
95°C; 40 cycles (15sec at 95°C, 1 min at 60°C), and data were analyzed using the 
Sequence Detection System Software v2.3 (Applied Biosystems ) and the 2-ΔΔCt 
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method (Livak, K.J., Schmittgen, T.D. Analysis of relative gene expression data 
using real-time quantitative PCR and the 2-ΔΔCt Method.  
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